Delaware | 16-1531026 | |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
Large accelerated filer | ý | Accelerated filer | ¨ | |
Non-accelerated filer | ¨ | Smaller reporting company | ¨ |
Page No. | ||
ITEM 1. | ||
ITEM 2. | ||
ITEM 3. | ||
ITEM 4. | ||
ITEM 1. | ||
ITEM 1A. | ||
ITEM 5. | ||
ITEM 6. | ||
As of | |||||||
July 1, 2016 | January 1, 2016 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 36,590 | $ | 82,478 | |||
Accounts receivable, net of allowance for doubtful accounts of $1.0 million in each period | 192,121 | 207,342 | |||||
Inventories | 276,279 | 252,166 | |||||
Refundable income taxes | 6,545 | 11,730 | |||||
Prepaid expenses and other current assets | 22,358 | 20,888 | |||||
Total current assets | 533,893 | 574,604 | |||||
Property, plant and equipment, net | 383,229 | 379,492 | |||||
Amortizing intangible assets, net | 880,254 | 893,977 | |||||
Indefinite-lived intangible assets | 90,288 | 90,288 | |||||
Goodwill | 980,839 | 1,013,570 | |||||
Deferred income taxes | 2,699 | 3,587 | |||||
Other assets | 31,335 | 26,618 | |||||
Total assets | $ | 2,902,537 | $ | 2,982,136 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Current portion of long-term debt | $ | 29,000 | $ | 29,000 | |||
Accounts payable | 99,135 | 84,362 | |||||
Income taxes payable | 2,347 | 3,221 | |||||
Accrued expenses | 86,800 | 97,257 | |||||
Total current liabilities | 217,282 | 213,840 | |||||
Long-term debt | 1,727,856 | 1,685,053 | |||||
Deferred income taxes | 220,440 | 221,804 | |||||
Other long-term liabilities | 13,486 | 10,814 | |||||
Total liabilities | 2,179,064 | 2,131,511 | |||||
Stockholders’ equity: | |||||||
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding | — | — | |||||
Common stock, $0.001 par value; 100,000,000 shares authorized; 30,935,792 and 30,664,119 shares issued, respectively; 30,801,205 and 30,601,167 shares outstanding, respectively | 31 | 31 | |||||
Additional paid-in capital | 630,077 | 620,470 | |||||
Treasury stock, at cost, 134,587 and 62,952 shares, respectively | (5,880 | ) | (3,100 | ) | |||
Retained earnings | 89,696 | 231,854 | |||||
Accumulated other comprehensive income | 9,549 | 1,370 | |||||
Total stockholders’ equity | 723,473 | 850,625 | |||||
Total liabilities and stockholders’ equity | $ | 2,902,537 | $ | 2,982,136 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Sales | $ | 348,382 | $ | 174,890 | $ | 680,620 | $ | 336,210 | |||||||
Cost of sales | 252,351 | 116,939 | 493,121 | 225,861 | |||||||||||
Gross profit | 96,031 | 57,951 | 187,499 | 110,349 | |||||||||||
Operating expenses: | |||||||||||||||
Selling, general and administrative expenses | 37,628 | 24,104 | 79,516 | 46,713 | |||||||||||
Research, development and engineering costs, net | 13,640 | 13,063 | 30,946 | 25,608 | |||||||||||
Other operating expenses, net | 15,494 | 7,750 | 36,634 | 15,605 | |||||||||||
Total operating expenses | 66,762 | 44,917 | 147,096 | 87,926 | |||||||||||
Operating income | 29,269 | 13,034 | 40,403 | 22,423 | |||||||||||
Interest expense, net | 27,908 | 1,206 | 55,525 | 2,326 | |||||||||||
Other expense (income), net | 674 | (107 | ) | (3,047 | ) | (1,658 | ) | ||||||||
Income (loss) before provision for income taxes | 687 | 11,935 | (12,075 | ) | 21,755 | ||||||||||
Provision for income taxes | 1,457 | 2,652 | 1,355 | 4,464 | |||||||||||
Net income (loss) | $ | (770 | ) | $ | 9,283 | $ | (13,430 | ) | $ | 17,291 | |||||
Earnings (loss) per share: | |||||||||||||||
Basic | $ | (0.03 | ) | $ | 0.36 | $ | (0.44 | ) | $ | 0.68 | |||||
Diluted | $ | (0.03 | ) | $ | 0.35 | $ | (0.44 | ) | $ | 0.66 | |||||
Weighted average shares outstanding: | |||||||||||||||
Basic | 30,767 | 25,473 | 30,743 | 25,369 | |||||||||||
Diluted | 30,767 | 26,313 | 30,743 | 26,264 | |||||||||||
Comprehensive Income (Loss) | |||||||||||||||
Net income (loss) | $ | (770 | ) | $ | 9,283 | $ | (13,430 | ) | $ | 17,291 | |||||
Other comprehensive income (loss): | |||||||||||||||
Foreign currency translation gain (loss) | (9,701 | ) | 214 | 9,059 | (1,611 | ) | |||||||||
Net change in cash flow hedges, net of tax | (1,247 | ) | (89 | ) | (880 | ) | (689 | ) | |||||||
Other comprehensive income (loss) | (10,948 | ) | 125 | 8,179 | (2,300 | ) | |||||||||
Comprehensive income (loss) | $ | (11,718 | ) | $ | 9,408 | $ | (5,251 | ) | $ | 14,991 |
Six Months Ended | |||||||
July 1, 2016 | July 3, 2015 | ||||||
Cash flows from operating activities: | |||||||
Net income (loss) | $ | (13,430 | ) | $ | 17,291 | ||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||
Depreciation and amortization | 45,048 | 18,194 | |||||
Debt related amortization included in interest expense | 3,581 | 387 | |||||
Stock-based compensation | 4,962 | 5,972 | |||||
Other non-cash gains, net | (108 | ) | (19 | ) | |||
Deferred income taxes | (3,776 | ) | (1,916 | ) | |||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | 11,858 | 3,691 | |||||
Inventories | (23,919 | ) | (10,851 | ) | |||
Prepaid expenses and other current assets | (3,124 | ) | (1,322 | ) | |||
Accounts payable | 12,844 | (848 | ) | ||||
Accrued expenses | (3,865 | ) | (7,239 | ) | |||
Income taxes | 3,683 | (846 | ) | ||||
Net cash provided by operating activities | 33,754 | 22,494 | |||||
Cash flows from investing activities: | |||||||
Acquisition of property, plant and equipment | (30,402 | ) | (22,174 | ) | |||
Purchase of cost and equity method investments, net | (2,198 | ) | (4,500 | ) | |||
Other investing activities | (682 | ) | 691 | ||||
Net cash used in investing activities | (33,282 | ) | (25,983 | ) | |||
Cash flows from financing activities: | |||||||
Principal payments of long-term debt | (16,500 | ) | (5,000 | ) | |||
Proceeds from issuance of long-term debt | 57,000 | — | |||||
Issuance of common stock | 610 | 5,056 | |||||
Payment of debt issuance costs | (781 | ) | — | ||||
Spin-off of cash and cash equivalents to Nuvectra Corporation | (76,256 | ) | — | ||||
Purchase of non-controlling interests | (6,818 | ) | — | ||||
Other financing activities | (3,983 | ) | (571 | ) | |||
Net cash used in financing activities | (46,728 | ) | (515 | ) | |||
Effect of foreign currency exchange rates on cash and cash equivalents | 368 | (482 | ) | ||||
Net decrease in cash and cash equivalents | (45,888 | ) | (4,486 | ) | |||
Cash and cash equivalents, beginning of period | 82,478 | 76,824 | |||||
Cash and cash equivalents, end of period | $ | 36,590 | $ | 72,338 |
Accumulated | |||||||||||||||||||||||||||||
Additional | Treasury | Other | Total | ||||||||||||||||||||||||||
Common Stock | Paid-In | Stock | Retained | Comprehensive | Stockholders’ | ||||||||||||||||||||||||
Shares | Amount | Capital | Shares | Amount | Earnings | Income | Equity | ||||||||||||||||||||||
At January 1, 2016 | 30,664 | $ | 31 | $ | 620,470 | (63 | ) | $ | (3,100 | ) | $ | 231,854 | $ | 1,370 | $ | 850,625 | |||||||||||||
Stock-based compensation | — | — | 4,962 | — | — | — | — | 4,962 | |||||||||||||||||||||
Net shares issued (acquired) under stock incentive plans | 272 | — | (596 | ) | (72 | ) | (2,780 | ) | — | — | (3,376 | ) | |||||||||||||||||
Spin-off of Nuvectra Corporation | — | — | 5,241 | — | — | (128,728 | ) | — | (123,487 | ) | |||||||||||||||||||
Net loss | — | — | — | — | — | (13,430 | ) | — | (13,430 | ) | |||||||||||||||||||
Total other comprehensive income, net | — | — | — | — | — | — | 8,179 | 8,179 | |||||||||||||||||||||
At July 1, 2016 | 30,936 | $ | 31 | $ | 630,077 | (135 | ) | $ | (5,880 | ) | $ | 89,696 | $ | 9,549 | $ | 723,473 |
1. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
2. | DIVESTITURE AND ACQUISITION |
Assets divested | |||
Cash and cash equivalents | $ | 76,256 | |
Other current assets | 977 | ||
Property, plant and equipment, net | 4,407 | ||
Amortizing intangible assets, net | 1,931 | ||
Goodwill | 40,830 | ||
Deferred income taxes | 6,446 | ||
Total assets divested | 130,847 | ||
Liabilities transferred | |||
Current liabilities | 2,119 | ||
Net assets divested | $ | 128,728 |
2. | DIVESTITURE AND ACQUISITION (Continued) |
Cash | $ | 478,490 | |
Fair value of Integer common stock | 245,368 | ||
Replacement stock options attributable to pre-acquisition service | 4,508 | ||
Total purchase consideration | $ | 728,366 |
Assets acquired | |||
Current assets | $ | 269,815 | |
Property, plant and equipment | 216,473 | ||
Amortizing intangible assets | 849,000 | ||
Indefinite-lived intangible assets | 70,000 | ||
Goodwill | 665,720 | ||
Other non-current assets | 1,629 | ||
Total assets acquired | 2,072,637 | ||
Liabilities assumed | |||
Current liabilities | 103,836 | ||
Debt assumed | 1,044,675 | ||
Other long-term liabilities | 195,760 | ||
Total liabilities assumed | 1,344,271 | ||
Net assets acquired | $ | 728,366 |
2. | DIVESTITURE AND ACQUISITION (Continued) |
Amortizing Intangible Assets | Fair Value Assigned | Weighted Average Amortization Period (Years) | Estimated Useful Life (Years) | Weighted Average Discount Rate | ||||||
Technology | $ | 160,000 | 7 | 19 | 11.5% | |||||
Customer lists | 689,000 | 14 | 29 | 11.5% | ||||||
$ | 849,000 | 13 | 27 | 11.5% | ||||||
Indefinite-lived Intangible Assets | ||||||||||
Trademarks and tradenames | $ | 70,000 | N/A | N/A | 11.5% |
2. | DIVESTITURE AND ACQUISITION (Continued) |
Three Months Ended | Six Months Ended | |||||||
July 3, 2015 | July 3, 2015 | |||||||
Sales | $ | 377,934 | $ | 736,351 | ||||
Net income | 4,709 | 5,675 | ||||||
Earnings per share: | ||||||||
Basic | $ | 0.15 | $ | 0.18 | ||||
Diluted | $ | 0.15 | $ | 0.18 |
2. | DIVESTITURE AND ACQUISITION (Continued) |
Six Months Ended | |||||||
(in thousands) | July 1, 2016 | July 3, 2015 | |||||
Noncash investing and financing activities: | |||||||
Common stock contributed to 401(k) Plan | $ | — | $ | 3,920 | |||
Property, plant and equipment purchases included in accounts payable | 9,696 | 1,446 | |||||
Purchase of technology included in accrued expenses | 1,000 | — | |||||
Divestiture of noncash assets | 54,591 | — | |||||
Divestiture of liabilities | 2,119 | — |
4. | INVENTORIES |
As of | |||||||
July 1, 2016 | January 1, 2016 | ||||||
Raw materials | $ | 114,454 | $ | 107,296 | |||
Work-in-process | 103,747 | 93,729 | |||||
Finished goods | 58,078 | 51,141 | |||||
Total | $ | 276,279 | $ | 252,166 |
5. | INTANGIBLE ASSETS |
Gross Carrying Amount | Accumulated Amortization | Foreign Currency Translation | Net Carrying Amount | ||||||||||||
At July 1, 2016 | |||||||||||||||
Purchased technology and patents | $ | 256,719 | $ | (92,017 | ) | $ | 2,397 | $ | 167,099 | ||||||
Customer lists | 759,987 | (50,389 | ) | 3,264 | 712,862 | ||||||||||
Other | 4,534 | (5,044 | ) | 803 | 293 | ||||||||||
Total amortizing intangible assets | $ | 1,021,240 | $ | (147,450 | ) | $ | 6,464 | $ | 880,254 | ||||||
At January 1, 2016 | |||||||||||||||
Purchased technology and patents | $ | 255,776 | $ | (83,708 | ) | $ | 1,444 | $ | 173,512 | ||||||
Customer lists | 761,857 | (40,815 | ) | (986 | ) | 720,056 | |||||||||
Other | 4,534 | (4,946 | ) | 821 | 409 | ||||||||||
Total amortizing intangible assets | $ | 1,022,167 | $ | (129,469 | ) | $ | 1,279 | $ | 893,977 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Cost of sales | $ | 4,240 | $ | 1,445 | $ | 8,480 | $ | 2,916 | |||||||
Selling, general and administrative expenses | 5,123 | 1,830 | 10,259 | 3,643 | |||||||||||
Research, development and engineering costs, net | 151 | 103 | 239 | 206 | |||||||||||
Total intangible asset amortization expense | $ | 9,514 | $ | 3,378 | $ | 18,978 | $ | 6,765 |
Estimated Amortization Expense | |||
Remainder of 2016 | $ | 18,934 | |
2017 | 44,050 | ||
2018 | 44,962 | ||
2019 | 45,044 | ||
2020 | 45,642 | ||
Thereafter | 681,622 | ||
Total estimated amortization expense | $ | 880,254 |
Trademarks and Tradenames | |||
At January 1, 2016 | $ | 90,288 | |
At July 1, 2016 | $ | 90,288 |
5. | INTANGIBLE ASSETS (Continued) |
Greatbatch Medical | QiG | Lake Region Medical | Total | ||||||||||||
At January 1, 2016 | $ | 303,929 | $ | 50,096 | $ | 659,545 | $ | 1,013,570 | |||||||
Goodwill divested (Note 2) | — | (40,830 | ) | — | (40,830 | ) | |||||||||
Purchase accounting adjustment (Note 2) | — | — | 3,932 | 3,932 | |||||||||||
Foreign currency translation | 91 | — | 4,076 | 4,167 | |||||||||||
At July 1, 2016 | $ | 304,020 | $ | 9,266 | $ | 667,553 | $ | 980,839 |
6. | DEBT |
As of | |||||||
July 1, 2016 | January 1, 2016 | ||||||
Senior secured term loan A | $ | 365,625 | $ | 375,000 | |||
Senior secured term loan B | 1,019,875 | 1,025,000 | |||||
9.125% senior notes due 2023 | 360,000 | 360,000 | |||||
Revolving line of credit | 55,000 | — | |||||
Less unamortized discount on term loan B and debt issuance costs | (43,644 | ) | (45,947 | ) | |||
Total debt | 1,756,856 | 1,714,053 | |||||
Less current portion of long-term debt | 29,000 | 29,000 | |||||
Total long-term debt | $ | 1,727,856 | $ | 1,685,053 |
6. | DEBT (Continued) |
6. | DEBT (Continued) |
Remaining in 2016 | $ | 14,500 | |
2017 | 31,344 | ||
2018 | 40,719 | ||
2019 | 47,750 | ||
2020 | 102,750 | ||
Thereafter | 1,563,437 | ||
Total | $ | 1,800,500 |
Instrument | Type of Hedge | Notional Amount | Start Date | End Date | Pay Fixed Rate | Receive Current Floating Rate | Fair Value July 1, 2016 | Balance Sheet Location | |||||||||||||||||
Interest Rate Swap | Cash Flow | $ | 200,000 | Jun-17 | Jun-20 | 1.1325 | % | N/A | $ | (1,819 | ) | Other Long-Term Liabilities |
6. | DEBT (Continued) |
At January 1, 2016 | $ | 4,791 | |
Amortization during the period | (496 | ) | |
At July 1, 2016 | $ | 4,295 |
Debt Issuance Costs | Unamortized Discount on TLB Facility | Total | |||||||||
At January 1, 2016 | $ | 35,908 | $ | 10,039 | $ | 45,947 | |||||
Financing costs incurred | 781 | — | 781 | ||||||||
Amortization during the period | (2,435 | ) | (649 | ) | (3,084 | ) | |||||
At July 1, 2016 | $ | 34,254 | $ | 9,390 | $ | 43,644 |
7. | BENEFIT PLANS |
At January 1, 2016 | $ | 7,121 | |
Net defined benefit cost | 390 | ||
Benefit payments | (70 | ) | |
Foreign currency translation | 116 | ||
At July 1, 2016 | $ | 7,557 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Service cost | $ | 110 | $ | 78 | $ | 218 | $ | 157 | |||||||
Interest cost | 45 | 15 | 88 | 30 | |||||||||||
Amortization of net loss | 47 | 12 | 93 | 26 | |||||||||||
Expected return on plan assets | (4 | ) | (3 | ) | (9 | ) | (6 | ) | |||||||
Net defined benefit cost | $ | 198 | $ | 102 | $ | 390 | $ | 207 |
8. | STOCK-BASED COMPENSATION |
• | Stock options: Holders of Integer stock option awards continued to hold stock options to purchase the same number of shares of Integer common stock at an adjusted exercise price and one new Nuvectra stock option for every three Integer stock options held as of the Record Date, which, in the aggregate, preserved the fair value of the overall awards granted. The adjusted exercise price for Integer stock options was equal to approximately 93% of the original exercise price. The stock option awards will continue to vest over their original vesting period. |
• | Restricted stock and restricted stock units: Holders of Integer restricted stock and restricted stock unit awards received one new share of Nuvectra restricted stock and restricted stock unit awards for every three Integer restricted stock and restricted stock unit awards held as of the Record Date. Integer restricted stock and restricted stock unit awards will continue to vest in accordance with their original performance metrics and over their original vesting period. |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Stock options | $ | 585 | $ | 663 | $ | 1,194 | $ | 1,282 | |||||||
Restricted stock and restricted stock units | 1,542 | 1,746 | 3,768 | 3,380 | |||||||||||
401(k) Plan stock contribution | — | 1,310 | — | 1,310 | |||||||||||
Total stock-based compensation expense | $ | 2,127 | $ | 3,719 | $ | 4,962 | $ | 5,972 | |||||||
Cost of sales | $ | 150 | $ | 1,094 | $ | 347 | $ | 1,354 | |||||||
Selling, general and administrative expenses | 1,528 | 2,148 | 3,183 | 3,909 | |||||||||||
Research, development and engineering costs, net | 116 | 477 | 293 | 709 | |||||||||||
Other operating expenses, net | 333 | — | 1,139 | — | |||||||||||
Total stock-based compensation expense | $ | 2,127 | $ | 3,719 | $ | 4,962 | $ | 5,972 |
Six Months Ended | |||||||
July 1, 2016 | July 3, 2015 | ||||||
Weighted average fair value | $ | 9.41 | $ | 12.18 | |||
Risk-free interest rate | 1.58 | % | 1.55 | % | |||
Expected volatility | 26 | % | 26 | % | |||
Expected life (in years) | 5 | 5 | |||||
Expected dividend yield | — | % | — | % |
8. | STOCK-BASED COMPENSATION (Continued) |
Number of Stock Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (In Years) | Aggregate Intrinsic Value (In Millions) | |||||||||
Outstanding at January 1, 2016 | 1,678,900 | $ | 28.32 | |||||||||
Granted | 235,856 | 50.69 | ||||||||||
Exercised | (27,540 | ) | 22.13 | |||||||||
Forfeited or expired | (37,708 | ) | 45.04 | |||||||||
Adjustment due to Spin-off | — | (2.02 | ) | |||||||||
Outstanding at July 1, 2016 | 1,849,508 | $ | 28.91 | 6.1 | $ | 14.3 | ||||||
Exercisable at July 1, 2016 | 1,443,941 | $ | 23.91 | 5.3 | $ | 14.3 |
Time-Vested Activity | Weighted Average Fair Value | |||||
Nonvested at January 1, 2016 | 39,235 | $ | 47.40 | |||
Granted | 46,474 | 51.48 | ||||
Vested | (11,422 | ) | 51.21 | |||
Forfeited | (8,165 | ) | 48.92 | |||
Nonvested at July 1, 2016 | 66,122 | $ | 49.42 |
Performance- Vested Activity | Weighted Average Fair Value | |||||
Nonvested at January 1, 2016 | 577,825 | $ | 25.11 | |||
Granted | 156,730 | 31.59 | ||||
Vested | (249,153 | ) | 15.86 | |||
Forfeited | (68,237 | ) | 32.33 | |||
Nonvested at July 1, 2016 | 417,165 | $ | 31.87 |
9. | OTHER OPERATING EXPENSES, NET |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
2014 investments in capacity and capabilities | $ | 5,126 | $ | 6,051 | $ | 9,279 | $ | 12,738 | |||||||
Orthopedic facilities optimization | 162 | 518 | 299 | 991 | |||||||||||
Legacy Lake Region Medical consolidations | 2,088 | — | 4,447 | — | |||||||||||
Acquisition and integration costs | 7,859 | 98 | 17,824 | 164 | |||||||||||
Asset dispositions, severance and other | 259 | 1,083 | 4,785 | 1,712 | |||||||||||
$ | 15,494 | $ | 7,750 | $ | 36,634 | $ | 15,605 |
• | Functions performed at the Company’s facility in Plymouth, MN to manufacture catheters and introducers will transfer into the Company’s existing facility in Tijuana, Mexico. This initiative will be substantially completed in the second half of 2016 and is dependent upon our customers’ validation and qualification of the transferred products. |
• | Functions performed at the Company’s facilities in Beaverton, OR and Raynham, MA to manufacture products for the portable medical market were transferred to a new facility in Tijuana, Mexico. Products manufactured at the Beaverton facility, which do not serve the portable medical market, were transferred to the Company’s Raynham facility. This initiative was substantially completed during the first quarter of 2016. |
• | The design engineering responsibilities previously performed at the Company’s Cleveland, OH facility were transferred to the Company’s facilities in Minnesota in 2015. |
• | The realignment of the Company’s commercial sales operations was completed in 2015. |
Severance and Retention | Accelerated Depreciation/Asset Write-offs | Other | Total | ||||||||||||
At January 1, 2016 | $ | 1,429 | $ | — | $ | 1,595 | $ | 3,024 | |||||||
Restructuring charges | — | 1,581 | 7,698 | 9,279 | |||||||||||
Write-offs | — | (1,581 | ) | — | (1,581 | ) | |||||||||
Cash payments | (1,235 | ) | — | (7,386 | ) | (8,621 | ) | ||||||||
At July 1, 2016 | $ | 194 | $ | — | $ | 1,907 | $ | 2,101 |
9. | OTHER OPERATING EXPENSES, NET (Continued) |
• | Severance and retention: approximately $11.0 million; |
• | Accelerated depreciation and asset write-offs: approximately $13.0 million; and |
• | Other: $21.0 million – $24.0 million |
Severance and Retention | Accelerated Depreciation/Asset Write-offs | Other | Total | ||||||||||||
At January 1, 2016 | $ | — | $ | — | $ | — | $ | — | |||||||
Restructuring charges | — | — | 299 | 299 | |||||||||||
Cash payments | — | — | (299 | ) | (299 | ) | |||||||||
At July 1, 2016 | $ | — | $ | — | $ | — | $ | — |
• | Employee costs: $5.0 million - $6.0 million; and |
• | Other: $8.0 million - $9.0 million. |
9. | OTHER OPERATING EXPENSES, NET (Continued) |
Employee Costs | Other | Total | |||||||||
At January 1, 2016 | $ | 3,667 | $ | 596 | $ | 4,263 | |||||
Restructuring charges | 3,428 | 1,019 | 4,447 | ||||||||
Cash payments | (4,768 | ) | (1,121 | ) | (5,889 | ) | |||||
At July 1, 2016 | $ | 2,327 | $ | 494 | $ | 2,821 |
10. | INCOME TAXES |
11. | COMMITMENTS AND CONTINGENCIES |
At January 1, 2016 | $ | 3,316 | |
Additions to warranty reserve | 1,163 | ||
Warranty claims settled | (1,427 | ) | |
At July 1, 2016 | $ | 3,052 |
11. | COMMITMENTS AND CONTINGENCIES (Continued) |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Addition in cost of sales | $ | 768 | $ | 420 | $ | 1,387 | $ | 664 | |||||||
Ineffective portion of change in fair value | — | — | — | — |
Instrument | Type of Hedge | Aggregate Notional Amount | Start Date | End Date | $/Peso | Fair Value | Balance Sheet Location | ||||||||||||
FX Contract | Cash flow | $ | 8,240 | Jan 2016 | Dec 2016 | 0.0584 | $ | (634 | ) | Accrued Expenses | |||||||||
FX Contract | Cash flow | $ | 5,591 | Apr 2016 | Dec 2016 | 0.0565 | $ | (251 | ) | Accrued Expenses |
12. | EARNINGS (LOSS) PER SHARE (“EPS”) |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Numerator for basic and diluted EPS: | |||||||||||||||
Net income (loss) | $ | (770 | ) | $ | 9,283 | $ | (13,430 | ) | $ | 17,291 | |||||
Denominator for basic EPS: | |||||||||||||||
Weighted average shares outstanding | 30,767 | 25,473 | 30,743 | 25,369 | |||||||||||
Effect of dilutive securities: | |||||||||||||||
Stock options, restricted stock and restricted stock units | — | 840 | — | 895 | |||||||||||
Denominator for diluted EPS | 30,767 | 26,313 | 30,743 | 26,264 | |||||||||||
Basic EPS | $ | (0.03 | ) | $ | 0.36 | $ | (0.44 | ) | $ | 0.68 | |||||
Diluted EPS | $ | (0.03 | ) | $ | 0.35 | $ | (0.44 | ) | $ | 0.66 |
Three Months Ended | Six Months Ended | ||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||
Time-vested stock options, restricted stock and restricted stock units | 1,916 | 276 | 1,916 | 297 | |||||||
Performance-vested restricted stock units | 417 | 60 | 417 | 56 |
13. | ACCUMULATED OTHER COMPREHENSIVE INCOME |
Defined Benefit Plan Liability | Cash Flow Hedges | Foreign Currency Translation Adjustment | Total Pre-Tax Amount | Tax | Net-of-Tax Amount | ||||||||||||||||||
At April 1, 2016 | $ | (1,179 | ) | $ | (1,827 | ) | $ | 22,369 | $ | 19,363 | $ | 1,134 | $ | 20,497 | |||||||||
Unrealized loss on cash flow hedges | — | (2,687 | ) | — | (2,687 | ) | 940 | (1,747 | ) | ||||||||||||||
Realized loss on foreign currency hedges | — | 768 | — | 768 | (268 | ) | 500 | ||||||||||||||||
Foreign currency translation loss | — | — | (9,701 | ) | (9,701 | ) | — | (9,701 | ) | ||||||||||||||
At July 1, 2016 | $ | (1,179 | ) | $ | (3,746 | ) | $ | 12,668 | $ | 7,743 | $ | 1,806 | $ | 9,549 |
Defined Benefit Plan Liability | Cash Flow Hedges | Foreign Currency Translation Adjustment | Total Pre-Tax Amount | Tax | Net-of-Tax Amount | ||||||||||||||||||
At January 1, 2016 | $ | (1,179 | ) | $ | (2,392 | ) | $ | 3,609 | $ | 38 | $ | 1,332 | $ | 1,370 | |||||||||
Unrealized loss on cash flow hedges | — | (2,741 | ) | — | (2,741 | ) | 959 | (1,782 | ) | ||||||||||||||
Realized loss on foreign currency hedges | — | 1,387 | — | 1,387 | (485 | ) | 902 | ||||||||||||||||
Foreign currency translation gain | — | — | 9,059 | 9,059 | — | 9,059 | |||||||||||||||||
At July 1, 2016 | $ | (1,179 | ) | $ | (3,746 | ) | $ | 12,668 | $ | 7,743 | $ | 1,806 | $ | 9,549 |
13. | ACCUMULATED OTHER COMPREHENSIVE INCOME (Continued) |
Defined Benefit Plan Liability | Cash Flow Hedges | Foreign Currency Translation Adjustment | Total Pre-Tax Amount | Tax | Net-of-Tax Amount | ||||||||||||||||||
At April 3, 2015 | $ | (1,181 | ) | $ | (3,480 | ) | $ | 9,625 | $ | 4,964 | $ | 1,734 | $ | 6,698 | |||||||||
Unrealized loss on cash flow hedges | — | (840 | ) | — | (840 | ) | 295 | (545 | ) | ||||||||||||||
Realized loss on foreign currency hedges | — | 420 | — | 420 | (147 | ) | 273 | ||||||||||||||||
Realized loss on interest rate swap hedges | — | 281 | — | 281 | (98 | ) | 183 | ||||||||||||||||
Foreign currency translation gain | — | — | 214 | 214 | — | 214 | |||||||||||||||||
At July 3, 2015 | $ | (1,181 | ) | $ | (3,619 | ) | $ | 9,839 | $ | 5,039 | $ | 1,784 | $ | 6,823 |
Defined Benefit Plan Liability | Cash Flow Hedges | Foreign Currency Translation Adjustment | Total Pre-Tax Amount | Tax | Net-of-Tax Amount | ||||||||||||||||||
At January 2, 2015 | $ | (1,181 | ) | $ | (2,558 | ) | $ | 11,450 | $ | 7,711 | $ | 1,412 | $ | 9,123 | |||||||||
Unrealized loss on cash flow hedges | — | (2,187 | ) | — | (2,187 | ) | 766 | (1,421 | ) | ||||||||||||||
Realized loss on foreign currency hedges | — | 664 | — | 664 | (232 | ) | 432 | ||||||||||||||||
Realized loss on interest rate swap hedges | — | 462 | — | 462 | (162 | ) | 300 | ||||||||||||||||
Foreign currency translation loss | — | — | (1,611 | ) | (1,611 | ) | — | (1,611 | ) | ||||||||||||||
At July 3, 2015 | $ | (1,181 | ) | $ | (3,619 | ) | $ | 9,839 | $ | 5,039 | $ | 1,784 | $ | 6,823 |
14. | FAIR VALUE MEASUREMENTS |
14. | FAIR VALUE MEASUREMENTS (Continued) |
Fair Value Measurements Using | ||||||||||||||||
At July 1, | Quoted Prices in Active Markets for Identical Assets | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||
Description | 2016 | (Level 1) | (Level 2) | (Level 3) | ||||||||||||
Liabilities | ||||||||||||||||
Foreign currency contracts (Note 11) | $ | 885 | $ | — | $ | 885 | $ | — | ||||||||
Interest rate swap (Note 6) | $ | 1,819 | $ | — | $ | 1,819 | $ | — |
14. | FAIR VALUE MEASUREMENTS (Continued) |
15. | BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION |
15. | BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION (Continued) |
• | Advanced Surgical, Orthopedics, and Portable Medical: Includes legacy Greatbatch Orthopedics and Portable Medical product line sales plus the legacy Lake Region Medical Advanced Surgical product line sales. Products include components, sub-assemblies, finished devices, implants, instruments and delivery systems for a range of surgical technologies to the advanced surgical market, including laparoscopy, orthopedics and general surgery, biopsy and drug delivery, joint preservation and reconstruction, arthroscopy, and engineered tubing solutions. Products also include life-saving and life-enhancing applications comprising of automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools. |
• | Cardio and Vascular: Includes the legacy Greatbatch Vascular product line sales plus the legacy Lake Region Medical Cardio and Vascular product line sales less the legacy Lake Region Medical Cardiac/Neuromodulation sales. Products include introducers, steerable sheaths, guidewires, catheters, and stimulation therapy components, subassemblies and finished devices that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery. |
• | Cardiac/Neuromodulation: Includes the legacy Greatbatch Cardiac/Neuromodulation and QiG sales plus the legacy Lake Region Medical Cardiac/Neuromodulation sales previously included in their Cardio and Vascular product line sales. Products include batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures used in implantable medical devices. |
• | Electrochem: Includes the legacy Greatbatch Energy, Military and Environmental product line sales. Products include primary (lithium) cells, and primary and secondary battery packs for demanding applications such as down hole drilling tools. |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Product line sales: | |||||||||||||||
Advanced Surgical, Orthopedics, and Portable Medical | $ | 104,317 | $ | 53,181 | $ | 195,646 | $ | 105,819 | |||||||
Cardio and Vascular | 144,219 | 12,907 | 277,869 | 23,263 | |||||||||||
Cardiac/Neuromodulation | 91,623 | 92,257 | 188,698 | 172,873 | |||||||||||
Electrochem | 9,819 | 16,545 | 21,491 | 34,255 | |||||||||||
Elimination of interproduct line sales | (1,596 | ) | — | (3,084 | ) | — | |||||||||
Total sales | 348,382 | 174,890 | $ | 680,620 | $ | 336,210 |
15. | BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION (Continued) |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Business segment sales: | |||||||||||||||
Greatbatch Medical | $ | 141,167 | $ | 172,786 | $ | 272,773 | $ | 329,763 | |||||||
QiG | 2,747 | 2,741 | 6,121 | 7,788 | |||||||||||
Lake Region Medical | 204,934 | — | 403,209 | — | |||||||||||
Elimination of intersegment sales(a) | (466 | ) | (637 | ) | (1,483 | ) | (1,341 | ) | |||||||
Total sales | 348,382 | 174,890 | $ | 680,620 | $ | 336,210 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Segment income (loss) from operations: | |||||||||||||||
Greatbatch Medical | $ | 14,564 | $ | 28,914 | $ | 25,579 | $ | 50,667 | |||||||
QiG | (700 | ) | (7,002 | ) | (5,909 | ) | (12,452 | ) | |||||||
Lake Region Medical | 27,356 | — | 48,555 | — | |||||||||||
Total segment income from operations | 41,220 | 21,912 | 68,225 | 38,215 | |||||||||||
Unallocated operating expenses | (11,951 | ) | (8,878 | ) | (27,822 | ) | (15,792 | ) | |||||||
Operating income | 29,269 | 13,034 | 40,403 | 22,423 | |||||||||||
Unallocated expenses, net | (28,582 | ) | (1,099 | ) | (52,478 | ) | (668 | ) | |||||||
Income (loss) before provision for income taxes | $ | 687 | $ | 11,935 | $ | (12,075 | ) | $ | 21,755 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Sales by geographic area: | |||||||||||||||
United States | $ | 204,090 | $ | 75,041 | $ | 406,213 | $ | 145,557 | |||||||
Non-Domestic locations: | |||||||||||||||
Puerto Rico | 39,344 | 37,415 | 78,472 | 71,431 | |||||||||||
Belgium | 20,491 | 16,018 | 38,657 | 33,385 | |||||||||||
Rest of world | 84,457 | 46,416 | 157,278 | 85,837 | |||||||||||
Total sales | $ | 348,382 | $ | 174,890 | $ | 680,620 | $ | 336,210 |
Three Months Ended | Six Months Ended | ||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||
Customer A | 17% | 20% | 18% | 21% | |||
Customer B | 15% | 18% | 15% | 18% | |||
Customer C | 13% | 12% | 13% | 13% | |||
Total | 45% | 50% | 46% | 52% |
15. | BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION (Continued) |
As of | |||||||
July 1, 2016 | January 1, 2016 | ||||||
United States | $ | 265,208 | $ | 264,556 | |||
Rest of world | 118,021 | 114,936 | |||||
Total | $ | 383,229 | $ | 379,492 |
16. | IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS |
16. | IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued) |
• | future sales, expenses and profitability; |
• | future development and expected growth of our business and industry; |
• | our ability to execute our business model and our business strategy; |
• | our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets; |
• | our ability to remain in compliance with our debt covenants; and |
• | projected capital expenditures. |
Three Months Ended | |||||||||||||||||||||||
July 1, 2016 | July 3, 2015 | ||||||||||||||||||||||
(in thousands except per share amounts) | Pre-Tax | Net Income | Per Diluted Share | Pre-Tax | Net Income | Per Diluted Share | |||||||||||||||||
Income (loss) and diluted EPS as reported (GAAP) | $ | 687 | $ | (770 | ) | $ | (0.03 | ) | $ | 11,935 | $ | 9,283 | $ | 0.35 | |||||||||
Adjustments: | |||||||||||||||||||||||
Amortization of intangibles(a) | 9,514 | 6,732 | 0.22 | 3,378 | 2,359 | 0.09 | |||||||||||||||||
IP related litigation (SG&A)(a)(b) | 285 | 185 | 0.01 | 1,459 | 948 | 0.04 | |||||||||||||||||
Consolidation and optimization expenses (OOE)(a)(c) | 7,376 | 5,975 | 0.19 | 6,569 | 5,361 | 0.20 | |||||||||||||||||
Acquisition and integration expenses (OOE)(a)(d) | 7,859 | 5,145 | 0.16 | 98 | 70 | — | |||||||||||||||||
Asset dispositions, severance and other (OOE)(a)(e) | 259 | 197 | 0.01 | 1,083 | 698 | 0.03 | |||||||||||||||||
Loss (gain) on cost and equity method investments, net (other expense (income), net)(a) | 124 | 81 | — | (42 | ) | (27 | ) | — | |||||||||||||||
R&D Tax Credit(f) | — | — | — | — | 400 | 0.02 | |||||||||||||||||
Taxes(a) | (8,559 | ) | — | — | (5,388 | ) | — | — | |||||||||||||||
Adjusted net income and diluted EPS (Non-GAAP)(g) | $ | 17,545 | $ | 17,545 | $ | 0.56 | $ | 19,092 | $ | 19,092 | $ | 0.73 | |||||||||||
Adjusted effective tax rate/diluted weighted average shares (a)(h) | 32.8 | % | 31,228 | 22.0 | % | 26,313 |
Six Months Ended | |||||||||||||||||||||||
July 1, 2016 | July 3, 2015 | ||||||||||||||||||||||
(in thousands except per share amounts) | Pre-Tax | Net Income | Per Diluted Share | Pre-Tax | Net Income | Per Diluted Share | |||||||||||||||||
Income (loss) and diluted EPS as reported (GAAP) | $ | (12,075 | ) | $ | (13,430 | ) | $ | (0.44 | ) | $ | 21,755 | $ | 17,291 | $ | 0.66 | ||||||||
Adjustments: | |||||||||||||||||||||||
Amortization of intangibles(a) | 18,978 | 13,423 | 0.43 | 6,765 | 4,725 | 0.18 | |||||||||||||||||
IP related litigation (SG&A)(a)(b) | 2,192 | 1,425 | 0.05 | 2,159 | 1,403 | 0.05 | |||||||||||||||||
Consolidation and optimization expenses (OOE)(a)(c) | 14,025 | 11,289 | 0.36 | 13,729 | 10,899 | 0.41 | |||||||||||||||||
Acquisition and integration expenses (OOE)(a)(d) | 17,824 | 11,656 | 0.37 | 164 | 116 | — | |||||||||||||||||
Asset dispositions, severance and other (OOE)(a)(e) | 4,785 | 4,423 | 0.14 | 1,712 | 1,132 | 0.04 | |||||||||||||||||
Gain on cost and equity method investments, net (other expense (income), net)(a) | (1,177 | ) | (765 | ) | (0.02 | ) | (540 | ) | (351 | ) | (0.01 | ) | |||||||||||
R&D Tax Credit(f) | — | — | — | — | 800 | 0.03 | |||||||||||||||||
Taxes(a) | (16,531 | ) | — | — | (9,729 | ) | — | — | |||||||||||||||
Adjusted net income and diluted EPS (Non-GAAP)(g) | $ | 28,021 | $ | 28,021 | $ | 0.90 | $ | 36,015 | $ | 36,015 | $ | 1.37 | |||||||||||
Adjusted effective tax rate/diluted weighted average shares (a)(h) | 37.1 | % | 31,257 | 21.3 | % | 26,264 |
(a) | The difference between pre-tax and net income amounts is the estimated tax impact related to the respective adjustment. Net income amounts are computed using a 35% U.S., Mexico, Germany and France statutory tax rate, a 0% Swiss tax rate, a 20% Netherlands statutory tax rate, a 25% Uruguay statutory tax rate, and a 12.5% Ireland statutory tax rate. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%. |
(b) | In 2013, we filed suit against AVX Corporation alleging they were infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and a federal jury awarded the Company $37.5 million in damages. To date, no gains have been recognized in connection with this litigation. |
(c) | During 2016 and 2015, we incurred costs primarily related to the transfer of our Beaverton, OR, portable medical and Plymouth, MN, vascular manufacturing operations to Tijuana, Mexico. Additionally, with the acquisition of Lake Region Medical, 2016 costs also include expenses incurred in connection with the closure of Lake Region Medical’s Arvada, CO, site and the consolidation of its two Galway, Ireland sites, which was initiated by Lake Region Medical in 2014. |
(d) | During 2016, we incurred acquisition and integration costs related to the acquisition of Lake Region Medical, which was acquired in October 2015. During 2015, we incurred costs related to the integration of CCC Medical Devices, which was acquired in August 2014. |
(e) | Costs primarily include legal and professional fees incurred in connection with the Spin-off, which was completed in March 2016. |
(f) | The 2015 Federal R&D tax credit was enacted during the fourth quarter of 2015 and has been permanently reinstated. Amounts assume that the tax credit was effective at the beginning of the year for 2015. |
(g) | The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total. |
(h) | The three and six-month 2016 adjusted diluted weighted average shares include 461,000 and 514,000 shares, respectively, related to outstanding equity awards that were not dilutive for GAAP diluted EPS purposes. |
• | The organic constant currency decline in sales as discussed above; |
• | A $26.7 million and $53.2 million increase in interest expense for the quarter and six month comparisons, respectively, due to the debt incurred in connection with the Lake Region Medical acquisition in October 2015; |
• | The additional 5 million shares issued in connection with the Lake Region Medical acquisition; |
• | The decrease in GAAP diluted EPS for the second quarter and six month periods was also attributable to $15.8 million and $38.8 million, respectively, of consolidation, IP related litigation, acquisition, integration and Spin-off related expenses compared to $9.2 million and $17.8 million, respectively, for the comparable 2015 periods. These costs are included in GAAP results, but are excluded from adjusted amounts; and |
• | The decrease in GAAP and adjusted diluted EPS for the second quarter and six month periods was partially offset by 1) $27.4 million and $48.6 million, respectively, of operating income added from Lake Region Medical; 2) approximately $8 million and $13 million, respectively, of synergies realized in connection with the Lake Region Medical acquisition; and 3) approximately $6 million of lower costs (primarily RD&E and SG&A) for the quarter and six month periods as a result of the Spin-off in March 2016. |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, | July 3, | July 1, | July 3, | ||||||||||||
(dollars in thousands) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Net income (loss) as reported (GAAP) | $ | (770 | ) | $ | 9,283 | $ | (13,430 | ) | $ | 17,291 | |||||
Interest expense | 27,908 | 1,206 | 55,525 | 2,326 | |||||||||||
Provision for income taxes | 1,457 | 2,652 | 1,355 | 4,464 | |||||||||||
Depreciation | 13,121 | 5,638 | 26,070 | 11,429 | |||||||||||
Amortization | 9,514 | 3,378 | 18,978 | 6,765 | |||||||||||
EBITDA (Non-GAAP) | 51,230 | 22,157 | 88,498 | 42,275 | |||||||||||
IP related litigation | 285 | 1,459 | 2,192 | 2,159 | |||||||||||
Stock-based compensation expense | 1,794 | 3,719 | 3,823 | 5,972 | |||||||||||
Consolidation and optimization expenses | 7,376 | 6,569 | 14,025 | 13,729 | |||||||||||
Acquisition and integration expenses | 7,859 | 98 | 17,824 | 164 | |||||||||||
Asset dispositions, severance and other | 259 | 1,083 | 4,785 | 1,712 | |||||||||||
Noncash (gain) loss on cost and equity method investments | 124 | (42 | ) | (515 | ) | (540 | ) | ||||||||
Adjusted EBITDA (Non-GAAP) | $ | 68,927 | $ | 35,043 | $ | 130,632 | $ | 65,471 | |||||||
Adjusted EBITDA as a % of sales (Non-GAAP) | 19.8 | % | 20.0 | % | 19.2 | % | 19.5 | % |
GAAP | Adjusted Comparable Basis | ||||||
High | Low | High | Low | ||||
Revenue | $1,396 | $1,376 | $1,395 | $1,375 | |||
Net Income | $13 | $9 | $86 | $82 | |||
Earnings per Diluted Share | $0.42 | $0.27 | $2.75 | $2.60 | |||
EBITDA | NA | NA | $305 | $295 |
Product Line | Product Development Opportunities | |
Advanced Surgical, Orthopedics, and Portable Medical | Developing a portfolio of single use products and instruments for the orthopedics market. | |
Developing a portfolio of wireless products for the portable medical and orthopedic markets. | ||
Cardio and Vascular | Developing a portfolio of catheter, wire-based, sensor and coating products for the cardio and vascular markets. | |
Cardiac/Neuromodulation | Developing next generation technology programs including the Gen 2 QHR battery, next generation filtered feedthroughs, high voltage capacitors and vertically integrated lead solutions. | |
Electrochem | Developing power solutions to advance performance and reliability of battery packs in critical environments. |
Initiative | Expected Expense | Expected Capital | Expected Benefit to Operating Income(a) | Expected Completion Date | ||||
2014 investments in capacity and capabilities | $42 - $48 | $25 - $28 | > $20 | 2016 | ||||
Orthopedic facilities optimization | $45 - $48 | $30 - $35 | $15 - $20 | 2017 | ||||
Legacy Lake Region Medical consolidations | $13 - $15 | $3 - $4 | $8 - $9 | 2016 |
(a) | Represents the annual benefit to our operating income expected to be realized from these initiatives through cost savings and/or increased capacity. These benefits will be phased in over time as the various initiatives are completed. |
• | Cardio and Vascular - Includes the legacy Greatbatch Vascular product line sales plus the legacy Lake Region Medical Cardio and Vascular product line sales less the legacy Lake Region Medical Cardiac/Neuromodulation sales. |
• | Cardiac/Neuromodulation - Includes the legacy Greatbatch Cardiac/Neuromodulation and QiG sales plus the legacy Lake Region Medical Cardiac/Neuromodulation sales previously included in their Cardio and Vascular product line sales. |
• | Electrochem - Includes the legacy Greatbatch Energy, Military and Environmental product line sales. |
Three Months Ended | ||||||||||||||
July 1, | July 3, | Change | ||||||||||||
2016 | 2015 | $ | % | |||||||||||
Sales: | ||||||||||||||
Advanced Surgical, Orthopedics, and Portable Medical | $ | 104,317 | $ | 53,181 | $ | 51,136 | 96 | % | ||||||
Cardio and Vascular | 144,219 | 12,907 | 131,312 | N/A | ||||||||||
Cardiac/Neuromodulation | 91,623 | 92,257 | (634 | ) | (1 | )% | ||||||||
Electrochem | 9,819 | 16,545 | (6,726 | ) | (41 | )% | ||||||||
Elimination of interproduct line sales | (1,596 | ) | — | (1,596 | ) | N/A | ||||||||
Total Sales | 348,382 | 174,890 | 173,492 | 99 | % | |||||||||
Cost of sales | 252,351 | 116,939 | 135,412 | 116 | % | |||||||||
Gross profit | 96,031 | 57,951 | 38,080 | 66 | % | |||||||||
Gross profit as a % of sales | 27.6 | % | 33.1 | % | ||||||||||
Selling, general and administrative expenses (“SG&A”) | 37,628 | 24,104 | 13,524 | 56 | % | |||||||||
SG&A as a % of sales | 10.8 | % | 13.8 | % | ||||||||||
Research, development and engineering costs, net (“RD&E”) | 13,640 | 13,063 | 577 | 4 | % | |||||||||
RD&E as a % of sales | 3.9 | % | 7.5 | % | ||||||||||
Other operating expenses, net | 15,494 | 7,750 | 7,744 | 100 | % | |||||||||
Operating income | 29,269 | 13,034 | 16,235 | 125 | % | |||||||||
Operating margin | 8.4 | % | 7.5 | % | ||||||||||
Interest expense, net | 27,908 | 1,206 | 26,702 | N/A | ||||||||||
Other expense (income), net | 674 | (107 | ) | 781 | N/A | |||||||||
Provision for income taxes | 1,457 | 2,652 | (1,195 | ) | (45 | )% | ||||||||
Effective tax rate | N/A | 22.2 | % | |||||||||||
Net income (loss) | $ | (770 | ) | $ | 9,283 | $ | (10,053 | ) | (108 | )% | ||||
Net margin | (0.2 | )% | 5.3 | % | ||||||||||
Diluted earnings (loss) per share | $ | (0.03 | ) | $ | 0.35 | $ | (0.38 | ) | (109 | )% |
Six Months Ended | ||||||||||||||
July 1, | July 3, | Change | ||||||||||||
2016 | 2015 | $ | % | |||||||||||
Sales: | ||||||||||||||
Advanced Surgical, Orthopedics, and Portable Medical | $ | 195,646 | $ | 105,819 | $ | 89,827 | 85 | % | ||||||
Cardio and Vascular | 277,869 | 23,263 | 254,606 | N/A | ||||||||||
Cardiac/Neuromodulation | 188,698 | 172,873 | 15,825 | 9 | % | |||||||||
Electrochem | 21,491 | 34,255 | (12,764 | ) | (37 | )% | ||||||||
Elimination of interproduct line sales | (3,084 | ) | — | (3,084 | ) | N/A | ||||||||
Total Sales | 680,620 | 336,210 | 344,410 | 102 | % | |||||||||
Cost of sales | 493,121 | 225,861 | 267,260 | 118 | % | |||||||||
Gross profit | 187,499 | 110,349 | 77,150 | 70 | % | |||||||||
Gross profit as a % of sales | 27.5 | % | 32.8 | % | ||||||||||
SG&A | 79,516 | 46,713 | 32,803 | 70 | % | |||||||||
SG&A as a % of sales | 11.7 | % | 13.9 | % | ||||||||||
RD&E | 30,946 | 25,608 | 5,338 | 21 | % | |||||||||
RD&E as a % of sales | 4.5 | % | 7.6 | % | ||||||||||
Other operating expenses, net | 36,634 | 15,605 | 21,029 | 135 | % | |||||||||
Operating income | 40,403 | 22,423 | 17,980 | 80 | % | |||||||||
Operating margin | 5.9 | % | 6.7 | % | ||||||||||
Interest expense, net | 55,525 | 2,326 | 53,199 | N/A | ||||||||||
Other income, net | (3,047 | ) | (1,658 | ) | (1,389 | ) | 84 | % | ||||||
Provision for income taxes | 1,355 | 4,464 | (3,109 | ) | (70 | )% | ||||||||
Effective tax rate | (11.2 | )% | 20.5 | % | ||||||||||
Net income (loss) | $ | (13,430 | ) | $ | 17,291 | $ | (30,721 | ) | (178 | )% | ||||
Net margin | (2.0 | )% | 5.1 | % | ||||||||||
Diluted earnings (loss) per share | $ | (0.44 | ) | $ | 0.66 | $ | (1.10 | ) | (167 | )% |
Change From Prior Year | |||||
Three Months | Six Months | ||||
Impact of Lake Region Medical(a) | (2.4 | )% | (3.4 | )% | |
Production efficiencies, volume and mix(b) | (5.8 | )% | (3.4 | )% | |
Performance-based compensation(c) | 1.9 | % | 0.9 | % | |
Price(d) | (0.5 | )% | (0.4 | )% | |
Other | 1.3 | % | 1.0 | % | |
Total percentage point change to gross profit as a percentage of sales | (5.5 | )% | (5.3 | )% |
(a) | Amount represents the impact to our Gross Margin related to Lake Region Medical, which was acquired in October 2015 and historically had lower Gross Margins than Greatbatch Medical. |
(b) | Our Gross Margin for 2016 was negatively impacted by lower production volumes, as well as a higher mix of sales of lower margin products partially offset by production efficiencies gained as a result of our investments in capacity and capabilities. |
(c) | Amount represents the change in performance-based compensation versus the prior year and is recorded based upon the actual results achieved. |
(d) | Our Gross Margin for 2016 was negatively impacted by price concessions given to our larger OEM customers in return for long-term volume commitments. |
Change From Prior Year | |||||||
Three Months | Six Months | ||||||
Performance-based compensation(a) | $ | (1,027 | ) | $ | (275 | ) | |
Legal fees(b) | (1,543 | ) | (581 | ) | |||
Nuvectra SG&A(c) | (2,058 | ) | (2,363 | ) | |||
Impact of Lake Region Medical acquisition(d) | 17,653 | 36,353 | |||||
Other | 499 | (331 | ) | ||||
Net increase in SG&A | $ | 13,524 | $ | 32,803 |
(a) | Amounts represent the change in performance-based compensation versus the prior year period and is recorded based upon actual results achieved. |
(b) | Amounts represent the change in legal costs compared to the prior year period and includes IP related defense costs, as well as other corporate initiatives. In 2013, we filed suit against one of our cardiac/neuromodulation competitors alleging they were infringing on our IP. In January 2016, a jury returned a verdict finding in favor of Integer and awarded us $37.5 million in damages. The finding is subject to post-trial proceedings, including a possible appeal by our competitor. We have not recorded any gains in connection with this litigation as no cash has been received. Costs associated with this litigation accounted for $1.2 million of the quarter over quarter decrease in SG&A expenses from 2015 to 2016 as the trial for this litigation concluded in the first quarter of 2016. |
(c) | Amounts represent the decrease in SG&A costs attributable to Nuvectra, which was spun-off in March 2016. |
(d) | Amounts represent the incremental SG&A expenses from Lake Region Medical, which was acquired in October 2015. |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
Research, development and engineering costs | $ | 15,180 | $ | 15,273 | $ | 33,378 | $ | 29,103 | |||||||
Less: cost reimbursements | (1,540 | ) | (2,210 | ) | (2,432 | ) | (3,495 | ) | |||||||
Total RD&E, net | $ | 13,640 | $ | 13,063 | $ | 30,946 | $ | 25,608 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 1, 2016 | July 3, 2015 | July 1, 2016 | July 3, 2015 | ||||||||||||
2014 investments in capacity and capabilities(a) | $ | 5,126 | $ | 6,051 | $ | 9,279 | $ | 12,738 | |||||||
Orthopedic facilities optimization(a) | 162 | 518 | 299 | 991 | |||||||||||
Legacy Lake Region Medical consolidations(a) | 2,088 | — | 4,447 | — | |||||||||||
Acquisition and integration costs(b) | 7,859 | 98 | 17,824 | 164 | |||||||||||
Asset dispositions, severance and other(c) | 259 | 1,083 | 4,785 | 1,712 | |||||||||||
Total other operating expenses, net | $ | 15,494 | $ | 7,750 | $ | 36,634 | $ | 15,605 |
(a) | Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for these initiatives. |
(b) | During the second quarter and first six months of 2016, we incurred $0.4 million and $1.8 million, respectively in transaction costs related to the acquisition of Lake Region Medical, which primarily included professional and consulting fees. Additionally, during the second quarter and first six months of 2016, we incurred $7.2 million and $16.0 million, respectively, in Lake Region Medical integration costs, which primarily included change-in-control payments to former Lake Region Medical executives, as well as professional, consulting, severance, retention, relocation, and travel costs. Refer to Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for acquisition and integration costs. |
(c) | During the first six months of 2016 and 2015, we incurred legal and professional costs in connection with the Spin-off of Nuvectra of $4.4 million ($0.08 million in the second quarter of 2016) and $1.5 million ($1.0 million in the second quarter of 2015), respectively. Refer to Note 2 “Divestiture and Acquisition” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional discussion on the Spin-off. |
As of | |||||||
(Dollars in thousands) | July 1, 2016 | January 1, 2016 | |||||
Cash and cash equivalents | $ | 36,590 | $ | 82,478 | |||
Working capital | $ | 316,611 | $ | 360,764 | |||
Current ratio | 2.46 | 2.69 |
a. | Evaluation of Disclosure Controls and Procedures |
b. | Changes in Internal Control Over Financial Reporting |
• | Lake Region Medical Holdings, Inc. |
ITEM 1. | LEGAL PROCEEDINGS |
ITEM 1A. | RISK FACTORS |
ITEM 5. | OTHER INFORMATION |
ITEM 6. | EXHIBITS |
Dated: | August 9, 2016 | INTEGER HOLDINGS CORPORATION | |||
By: | /s/ Thomas J. Hook | ||||
Thomas J. Hook | |||||
President and Chief Executive Officer | |||||
(Principal Executive Officer) | |||||
By: | /s/ Michael Dinkins | ||||
Michael Dinkins | |||||
Executive Vice President and Chief Financial Officer | |||||
(Principal Financial Officer) | |||||
By: | /s/ Thomas J. Mazza | ||||
Thomas J. Mazza | |||||
Vice President, Corporate Controller and Treasurer | |||||
(Principal Accounting Officer) |
Exhibit No. | Description | |
3.1* | Restated Certificate of Incorporation of Integer Holdings Corporation | |
3.2* | By-laws of Integer Holdings Corporation | |
10.1* | Amendment No. 1 to the Transition Services Agreement between Greatbatch, Inc. and Nuvectra Corporation | |
10.2* | Employment Agreement, dated August 5, 2016, between Integer Holdings Corporation and Thomas J. Hook | |
10.3* | Amended and Restated Change of Control Agreement, dated August 5, 2016, between Integer Holdings Corporation and Thomas J. Hook | |
31.1* | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act. | |
31.2* | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act. | |
32.1** | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
101.INS* | XBRL Instance Document | |
101.SCH* | XBRL Extension Schema Document | |
101.CAL* | XBRL Extension Calculation Linkbase Document | |
101.LAB* | XBRL Extension Label Linkbase Document | |
101.PRE* | XBRL Extension Presentation Linkbase Document | |
101.DEF* | XBRL Extension Definition Linkbase Document |
1. | The name of the corporation is INTEGER HOLDINGS CORPORATION (the “Corporation”). |
2. | The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on June 13, 1997 under the name WGL Holdings, Inc. A subsequent Amended and Restated Certificate of Incorporation under the name Wilson Greatbatch Technologies, Inc. was filed with the Secretary of State of the State of Delaware on September 25, 2000, which has been subsequently amended. |
3. | That at a meeting of the Board of Directors of the Corporation, resolutions were duly adopted setting forth a proposed restatement of the Amended and Restated Certificate of Incorporation of the Corporation. |
4. | That said restatement was duly adopted in accordance with the provisions of Section 245 of the General Corporation Law of the State of Delaware. The restatement only restates and integrates and does not further amend the provisions of the Corporation’s Amended and Restated Certificate of Incorporation as theretofore amended, and that there is no discrepancy between those provisions and the provisions of the Restated Certificate of Incorporation set forth herein. |
5. | The Restated Certificate of Incorporation is hereby restated to read in its entirety as follows: |
(i) | 100,000,000 shares of Preferred Stock, $.001 par value per share, and |
(ii) | 100,000,000 shares of Common Stock, $.001 par value per share. |
INTEGER HOLDINGS CORPORATION | |||
By: | /s/ Timothy G. McEvoy | ||
Name: | Timothy G. McEvoy | ||
Title: | Senior Vice President, Secretary and General Counsel |
• | A report on all expenses submitted by Nuvectra field sales representatives, Paul Hanchin, Tom Hickman, Alan Mock, Jennifer Armstrong and Scott Drees; |
• | A report listing all business meals over $75 that involves only one attendee, such report to include the actual report and receipts submitted by the applicable Nuvectra employee; |
• | A report listing all business meals over $300 regardless of the number of attendees, such report to include the actual report and receipts submitted by the applicable Nuvectra employee; and |
• | A report listing all expense reports submitted in a month where the aggregate amount of expenses for the applicable Nuvectra employee is more than $2,000. |
GREATBATCH, INC. | ||||
By: | /s/ Thomas J. Mazza | |||
Name: | Thomas J. Mazza | |||
Title: | Vice President & Corporate Controller |
NUVECTRA CORPORATION | ||||
By: | /s/ Walter Berger | |||
Name: | Walter Berger | |||
Title: | Chief Financial Officer |
(1) | All stock options, restricted stock and/or other equity-based awards granted to the Executive which vest based on the passage of time which have not yet vested on the date the Executive is terminated on account of Executive’s permanent disability, will become fully vested on the date the Executive’s employment is terminated. |
(2) | All stock options, restricted stock and/or other equity-based awards granted to the Executive which vest based on achievement of performance metrics with respect to which the Executive has not yet vested on the date Executive is terminated on account of Executive’s permanent disability will continue in effect and will become vested to the extent provided for in the plan or award agreement under which such awards are granted. |
(1) | All stock options, restricted stock and/or other equity-based awards granted to the Executive which vest based on the passage of time which have not yet vested on the date of the Executive’s death, will become fully vested on the date of the Executive’s death. |
(2) | All stock options, restricted stock and/or other equity-based awards granted to the Executive which vest based on achievement of performance metrics with respect to which the Executive has not yet vested on the date of Executive’s death will continue in effect will become vested to the extent provided for in the plan or award agreement under which such awards are granted. |
(1) | All stock options, restricted stock and/or other equity-based awards granted to the Executive which vest based on the passage of time which have not yet vested on the date of the Executive’s termination without cause, will become fully vested on the date of the Executive’s termination without cause. |
(2) | With respect to all stock options, restricted stock and/or other equity-based awards granted to the Executive which vest based on achievement of performance metrics with respect to which the Executive has not yet vested on the date of Executive’s termination without cause (“Termination Date”), they will continue in effect, and be eligible for vesting after such termination of employment based on the achievement of the performance metrics to the extent (if any) that the plan or award agreement under which such awards so provides and |
(3) | For the purposes of clause (2) above, a partial calendar month shall be taken into account as a fraction of a month, the numerator of which is equal to the number of days which have elapsed in such calendar month through the Executive’s Termination Date, and the denominator of which is the total number of days in such calendar month. The Corporation shall notify the Executive of the number of options or restricted shares (or other equity awards) which vested at such time as awards for the plan year are generally determined to executives who are actively employed by the Company. |
/s/ Thomas J. Hook | ||
Thomas J. Hook | ||
INTEGER HOLDINGS CORPORATION | ||
/s/ Bill R. Sanford | ||
Bill R. Sanford, Chairman of the Board | ||
and | ||
/s/ Peter H. Soderberg | ||
Peter H. Soderberg | ||
Chair, Compensation and Organization Committee |
INTEGER HOLDINGS CORPORATION: | ||||
By: | /s/ Timothy G. McEvoy | |||
Timothy G. McEvoy | ||||
Senior Vice President, General Counsel & Secretary |
EXECUTIVE: | ||||
By: | /s/ Thomas J. Hook | |||
Thomas J. Hook | ||||
1. | I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended July 1, 2016 of Integer Holdings Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditor and the audit committee of registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: | August 9, 2016 | /s/ Thomas J. Hook | |
Thomas J. Hook | |||
President and Chief Executive Officer | |||
(Principal Executive Officer) |
1. | I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended July 1, 2016 of Integer Holdings Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditor and the audit committee of registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: | August 9, 2016 | /s/ Michael Dinkins | |
Michael Dinkins | |||
Executive Vice President and Chief Financial Officer | |||
(Principal Financial Officer) |
Dated: | August 9, 2016 | /s/ Thomas J. Hook | |
Thomas J. Hook | |||
President and Chief Executive Officer | |||
(Principal Executive Officer) | |||
Dated: | August 9, 2016 | /s/ Michael Dinkins | |
Michael Dinkins | |||
Executive Vice President and Chief Financial Officer | |||
(Principal Financial Officer) |
Document and Entity Information - shares |
6 Months Ended | |
---|---|---|
Jul. 01, 2016 |
Aug. 03, 2016 |
|
Document and Entity Information [Abstract] | ||
Entity Registrant Name | INTEGER HOLDINGS CORPORATION | |
Entity Central Index Key | 0001114483 | |
Document Type | 10-Q | |
Document Period End Date | Jul. 01, 2016 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2016 | |
Document Fiscal Period Focus | Q2 | |
Current Fiscal Year End Date | --12-30 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 30,801,205 |
Condensed Consolidated Balance Sheets - Unaudited (Parenthetical) - USD ($) $ in Millions |
Jul. 01, 2016 |
Jan. 01, 2016 |
---|---|---|
Current assets: | ||
Allowance for doubtful accounts | $ 1.0 | $ 1.0 |
Stockholders’ equity: | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 100,000,000 | 100,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 30,935,792 | 30,664,119 |
Common stock, shares outstanding | 30,801,205 | 30,601,167 |
Treasury stock, shares | 134,587 | 62,952 |
Condensed Consolidated Statements of Operations and Comprehensive Income - Unaudited - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Income Statement [Abstract] | ||||
Sales | $ 348,382 | $ 174,890 | $ 680,620 | $ 336,210 |
Cost of sales | 252,351 | 116,939 | 493,121 | 225,861 |
Gross profit | 96,031 | 57,951 | 187,499 | 110,349 |
Operating expenses: | ||||
Selling, general and administrative expenses | 37,628 | 24,104 | 79,516 | 46,713 |
Research, development and engineering costs, net | 13,640 | 13,063 | 30,946 | 25,608 |
Other operating expenses, net | 15,494 | 7,750 | 36,634 | 15,605 |
Total operating expenses | 66,762 | 44,917 | 147,096 | 87,926 |
Operating income | 29,269 | 13,034 | 40,403 | 22,423 |
Interest expense, net | 27,908 | 1,206 | 55,525 | 2,326 |
Other expense (income), net | 674 | (107) | (3,047) | (1,658) |
Income (loss) before provision for income taxes | 687 | 11,935 | (12,075) | 21,755 |
Provision for income taxes | 1,457 | 2,652 | 1,355 | 4,464 |
Net income (loss) | $ (770) | $ 9,283 | $ (13,430) | $ 17,291 |
Earnings (loss) per share: | ||||
Basic | $ (0.03) | $ 0.36 | $ (0.44) | $ 0.68 |
Diluted | $ (0.03) | $ 0.35 | $ (0.44) | $ 0.66 |
Weighted average shares outstanding: | ||||
Basic | 30,767 | 25,473 | 30,743 | 25,369 |
Diluted | 30,767 | 26,313 | 30,743 | 26,264 |
Comprehensive Income (Loss) | ||||
Net income (loss) | $ (770) | $ 9,283 | $ (13,430) | $ 17,291 |
Foreign currency translation gain (loss) | (9,701) | 214 | 9,059 | (1,611) |
Net change in cash flow hedges, net of tax | (1,247) | (89) | (880) | (689) |
Other comprehensive income (loss) | (10,948) | 125 | 8,179 | (2,300) |
Comprehensive income (loss) | $ (11,718) | $ 9,408 | $ (5,251) | $ 14,991 |
Condensed Consolidated Statement of Stockholders' Equity - Unaudited - 6 months ended Jul. 01, 2016 - USD ($) shares in Thousands, $ in Thousands |
Total |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Treasury Stock [Member] |
Retained Earnings [Member] |
Accumulated Other Comprehensive Income (Loss) [Member] |
---|---|---|---|---|---|---|
Balance, shares at Jan. 01, 2016 | 30,664 | (63) | ||||
Balance at Jan. 01, 2016 | $ 850,625 | $ 31 | $ 620,470 | $ (3,100) | $ 231,854 | $ 1,370 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Stock-based compensation | 4,962 | 4,962 | ||||
Net shares issued under stock incentive plans, shares | 272 | (72) | ||||
Net shares issued (acquired) under stock incentive plans | (3,376) | $ 0 | (596) | $ (2,780) | ||
Spin-off of Nuvectra Corporation | (123,487) | 5,241 | (128,728) | |||
Net income (loss) | (13,430) | (13,430) | ||||
Total other comprehensive income, net | 8,179 | 8,179 | ||||
Balance, shares at Jul. 01, 2016 | 30,936 | (135) | ||||
Balance at Jul. 01, 2016 | $ 723,473 | $ 31 | $ 630,077 | $ (5,880) | $ 89,696 | $ 9,549 |
Summary of Significant Accounting Policies |
6 Months Ended |
---|---|
Jul. 01, 2016 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Integer Holdings Corporation and its subsidiaries (collectively “Integer” or the “Company”) for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. The January 1, 2016 condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 1, 2016. The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The second quarter of 2016 and 2015 each contained 13 weeks, and ended on July 1, and July 3, respectively. Effective June 30, 2016, the Company changed its name from Greatbatch, Inc. to Integer Holdings Corporation. The new name represents the union of the Greatbatch Medical, Lake Region Medical and Electrochem brands. Integer, as in whole or complete, signifies the Company’s more comprehensive products and service offerings, and a new dimension in its combined capabilities. Nature of Operations – On October 27, 2015, the Company acquired all of the outstanding common stock of Lake Region Medical Holdings, Inc. (“Lake Region Medical”). As a result, the Company now has three reportable segments: Greatbatch Medical, QiG Group (“QiG”) and Lake Region Medical. On March 14, 2016, Integer completed the spin-off of a portion of its QiG segment through a tax-free distribution of all of the shares of its QiG Group, LLC subsidiary to the stockholders of Integer on a pro rata basis (the “Spin-off”). See Note 2 “Divestiture and Acquisition” for further description of these transactions. As a result of the Lake Region Medical acquisition and the Spin-off, the Company is in the process of re-evaluating its internal financial reporting structure, which may change its product line and segment reporting in the future. This process is expected to be finalized in 2016. Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise. These products include medical devices and components for the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets among others. The QiG segment focuses on the design and development of complete medical device systems and components. QiG seeks to assist customers in accelerating the velocity of innovation while delivering an optimized supply chain and critical cost efficiencies. The medical devices QiG designs and develops are full product solutions that utilize the medical technology expertise and capabilities residing within Greatbatch Medical and Lake Region Medical. See Note 2 “Divestiture and Acquisition” for further description of the Spin-off and how it impacted the Company’s QiG segment. Lake Region Medical has operated as a segment of Integer since it was acquired during the fourth quarter of 2015. This segment specializes in the design, development, and manufacturing of products across the medical component and device spectrum, primarily serving the cardio, vascular and advanced surgical markets. Lake Region Medical offers fully integrated outsourced manufacturing, regulatory and engineering services, contract manufacturing, finished device assembly services, original device development, and supply chain management to its customers. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. |
Divestiture and Acquisition |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Divestiture and Acquisition [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DIVESTITURE AND ACQUISITION | DIVESTITURE AND ACQUISITION Spin-off of Nuvectra Corporation On March 14, 2016, Integer completed the spin-off of a portion of its QiG segment through a tax-free distribution of all of the shares of its QiG Group, LLC subsidiary to the stockholders of Integer on a pro rata basis. Immediately prior to completion of the Spin-off, QiG Group, LLC was converted into a corporation organized under the laws of Delaware and changed its name to Nuvectra Corporation (“Nuvectra”). On March 14, 2016, each of the Company’s stockholders of record as of the close of business on March 7, 2016 (the “Record Date”) received one share of Nuvectra common stock for every three shares of Integer common stock held as of the Record Date. Upon completion of the Spin-off, Nuvectra became an independent publicly traded company whose common stock is listed on the NASDAQ stock exchange under the symbol “NVTR.” The portion of the QiG segment spun-off consisted of QiG Group, LLC and its subsidiaries: (i) Algostim, LLC (“Algostim”), (ii) PelviStim LLC (“PelviStim”), and (iii) the Company’s NeuroNexus Technologies (“NeuroNexus”) subsidiary. The operations of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”) and certain other existing QiG research and development capabilities were retained by Integer and not included as part of the Spin-off. As the Company continues to focus on the design and development of complete medical device systems and components, and more specifically on medical device systems and components in the neuromodulation market, the Spin-off was not considered a strategic shift that had a major effect on the Company’s operations and financial results. Accordingly, the Spin-off is not presented as a discontinued operation in the Company’s Condensed Consolidated Financial Statements. The results of Nuvectra are included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) through the date of the Spin-off. In connection with the Spin-off, during the first quarter of 2016, the Company made a cash capital contribution of $75 million to Nuvectra and divested the following assets and liabilities (in thousands):
For the first quarter of 2016, Nuvectra contributed a pre-tax loss of $5.2 million to the Company’s results of operations. Nuvectra contributed a pre-tax loss of $6.2 million and $11.7 million, respectively, to the Company’s results of operations for the three and six month periods ended July 3, 2015. In connection with the Spin-off, on March 14, 2016, Integer entered into several agreements with Nuvectra that govern its post Spin-off relationship with Nuvectra, including a Separation and Distribution Agreement, Tax Matters Agreement, Employee Matters Agreement and Transition Services Agreement. The Transition Services Agreement contains customary mutual indemnification provisions. Amounts earned by Integer under the Transition Services Agreement were immaterial for the six month period ended July 1, 2016. Accounts Receivable, Net within the Condensed Consolidated Balance Sheet at July 1, 2016 includes $4.6 million due from Nuvectra for payments made by the Company on Nuvectra’s behalf. Acquisition of Lake Region Medical Holdings, Inc. On October 27, 2015, the Company acquired all of the outstanding common stock of Lake Region Medical Holdings, Inc. for a total purchase price, including debt assumed, of approximately $1.77 billion. Lake Region Medical specializes in the design, development, and manufacturing of products across the medical component and device spectrum primarily serving the cardio, vascular and advanced surgical markets.
The aggregate consideration paid to the stockholders and equity award holders of Lake Region Medical consisted of the following (in thousands):
The fair value of the Integer common stock issued as part of the consideration was determined based upon the closing stock price of Integer’s shares as of the acquisition date. The fair value of the Integer stock options issued as part of the consideration was determined utilizing a Black-Scholes option pricing model as of the acquisition date. Concurrent with the closing of the acquisition, the Company repaid all of the outstanding debt of Lake Region Medical of approximately $1.0 billion. The cash portion of the purchase price and the repayment of Lake Region Medical’s debt was primarily funded through a new senior secured credit facility and the issuance of senior notes. See Note 6 “Debt” for additional information regarding the Company’s debt. The Company believes that the combination of Greatbatch and Lake Region Medical brings together two highly complementary organizations that can provide a new level of industry leading capabilities and services to OEM customers while building value for stockholders. Through this acquisition, the Company believes that it will be at the forefront of innovating technologies and products that help change the face of healthcare, providing its customers with a distinct advantage as they bring complete systems and solutions to market. In turn, Integer’s customers will be able to accelerate patient access to life enhancing therapies. The transaction is consistent with Integer's strategy of achieving profitable growth and continuous improvement to drive margin expansion. This transaction was accounted for under the acquisition method of accounting. Accordingly, the cost of the acquisition was allocated to the Lake Region Medical assets acquired and liabilities assumed based on their fair values as of the closing date of the acquisition, with the amount exceeding the fair value of the net assets acquired recorded as goodwill. The value assigned to certain assets and liabilities are preliminary and are subject to revision as more detailed analysis is completed and additional information about the fair value of assets acquired and liabilities assumed become available. The final allocation may include changes to the acquisition date fair value of goodwill, deferred taxes, as well as operating assets and liabilities, some of which may result in material adjustments. Measurement-period adjustments made during the first six months of 2016 were primarily to goodwill ($3.9 million) and deferred tax liabilities ($2.6 million), and did not impact the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). The following table summarizes the preliminary allocation of the Lake Region Medical purchase price to the assets acquired and liabilities assumed (in thousands):
The preliminary fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations. The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions. Current Assets and Liabilities – The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities. The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the market approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $23.0 million. This step-up in the fair value of inventory was amortized as the inventory to which the step-up relates was sold and was fully amortized as of January 1, 2016. Property, Plant and Equipment – The fair value of PP&E acquired was estimated by applying the cost approach for personal property, buildings and building improvements and the market approach for land. The cost approach was applied by developing a replacement cost and adjusting for depreciation and obsolescence. The value of the land acquired was derived from market prices for comparable properties. Intangible Assets – The purchase price was allocated to intangible assets as follows (dollars in thousands):
The weighted average amortization period is less than the estimated useful life, as the Company is using an accelerated amortization method, which approximates the distribution of cash flows used to fair value those intangible assets. Technology – Technology consists of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by Lake Region Medical and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate that ranged from 0.5% to 7%. The estimated useful life of the technology is based upon management’s estimate of the product life cycle associated with the technology before it will be replaced by new technologies.
Customer Lists – Customer lists represent the estimated fair value of non-contractual customer relationships Lake Region Medical had as of the acquisition date. The primary customers of Lake Region Medical include large OEMs in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The estimated useful life of the existing customer base was based upon the historical customer annual attrition rate of 5%, as well as management’s understanding of the industry and product life cycles. Trademarks and Tradenames – Trademarks and tradenames represent the estimated fair value of Lake Region Medical’s corporate and product names. These tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the trademarks and tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a royalty rate that ranged from 0.25% to 1%. Trademarks and tradenames were assumed to have an indefinite useful life based upon the significant value the Lake Region Medical name has with OEMs in the medical component and device industries, their long history of being an industry leader and producing quality and innovative components, and given management’s current intention of using this tradename indefinitely, which was assumed to be consistent with what a reasonable market participant would also assume. Goodwill – The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including the value of Lake Region Medical’s highly trained assembled work force and management team, the incremental value resulting from Lake Region Medical’s capabilities and services to OEMs, enhanced synergies, and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the acquisition was allocated to the Lake Region Medical segment and is not deductible for tax purposes. Long-term Debt – The fair value of long-term debt was assumed to be equal to what was paid by Integer at the time of closing of the acquisition in order to retire the debt, including prepayment penalties and fees. Statements of Operations and Comprehensive Income (Loss) The operating results of Lake Region Medical have been included in the Company’s Lake Region Medical segment from the date of acquisition. For the six months ended July 1, 2016, Lake Region Medical added $403.2 million to the Company’s revenue and decreased the Company’s net loss by approximately $16.5 million. Unaudited Pro Forma Financial Information The following unaudited pro forma information presents the consolidated results of operations of the Company and Lake Region Medical as if that acquisition occurred as of the beginning of fiscal year 2014 (in thousands, except per share amounts):
The unaudited pro forma financial information presents the combined operating results of Integer and Lake Region Medical with the results prior to the acquisition date adjusted to include the pro forma impact of the amortization of acquired intangible assets, the adjustment to interest expense reflecting the amount borrowed in connection with the acquisition at Integer’s interest rates, and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rate. The unaudited pro forma consolidated basic and diluted earnings per share calculations are based on the consolidated basic and diluted weighted average shares of Integer outstanding for the respective period plus an adjustment for the additional shares and stock options issued in connection with the Lake Region Medical acquisition as discussed above. The unaudited pro forma financial information is presented for illustrative purposes only and does not reflect the realization of potential cost savings, and any related integration costs. Costs savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These pro forma results do not purport to be indicative of the results that would have been obtained by the combined company, or to be a projection of results that may be obtained in the future by the combined company. |
Supplemental Cash Flow Information |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Cash Flow Elements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUPPLEMENTAL CASH FLOW INFORMATION | SUPPLEMENTAL CASH FLOW INFORMATION
|
Inventories |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INVENTORIES | INVENTORIES Inventories are comprised of the following (in thousands):
|
Intangible Assets |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INTANGIBLE ASSETS | INTANGIBLE ASSETS Amortizing intangible assets are comprised of the following (in thousands):
During the first quarter of 2016, the Company made an asset purchase of technology totaling $2.0 million, which is being amortized over a weighted average period of approximately 15 years. Aggregate intangible asset amortization expense is comprised of the following (in thousands):
Estimated future intangible asset amortization expense based on the carrying value as of July 1, 2016 is as follows (in thousands):
Indefinite-lived intangible assets are comprised of the following (in thousands):
The change in goodwill is as follows (in thousands):
|
Debt |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DEBT | DEBT Long-term debt is comprised of the following (in thousands):
Senior Secured Credit Facilities - In connection with the Lake Region Medical acquisition, on October 27, 2015, the Company replaced its existing credit facility with new senior secured credit facilities (the “Senior Secured Credit Facilities”) consisting of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), (ii) a $375 million term loan A facility (the “TLA Facility”), and (iii) a $1,025 million term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB facility was issued at a 1% discount. Term Loan Facilities The TLA Facility and TLB Facility mature on October 27, 2021 and October 27, 2022, respectively. Interest rates on the TLA Facility, as well as the Revolving Credit Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.75% and 2.25%, based on the Company’s Total Net Leverage Ratio, as defined in the Senior Secured Credit Facilities agreement or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.75% and 3.25%, based on the Company’s Total Net Leverage Ratio. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 3.25% or (ii) the applicable LIBOR rate plus 4.25%, with LIBOR subject to a 1.00% floor. Subject to certain conditions, one or more incremental term loan facilities may be added to the Term Loan Facilities so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25:1.00. As of July 1, 2016, the estimated fair value of the TLB Facility was approximately $1,011 million, based on quoted market prices for the debt, recent sales prices for the debt and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy. The par amount of the TLA Facility approximated its fair value as of July 1, 2016 based upon the debt being variable rate in nature.
Revolving Credit Facility The Revolving Credit Facility matures on October 27, 2020. The Revolving Credit Facility also includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25%, depending on the Company’s Total Net Leverage Ratio. As of July 1, 2016, the Company had $55 million of outstanding borrowings on the Revolving Credit Facility and an available borrowing capacity of $134.1 million after giving effect to $10.9 million of outstanding standby letters of credit. Subject to certain conditions, commitments under the Revolving Credit Facility may be increased through an incremental revolving facility so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25:1.00. Covenants The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum Total Net Leverage Ratio of 6.50:1.00, subject to step downs beginning in the fourth quarter of 2016 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 3.00:1.00. The TLB Facility does not contain any financial maintenance covenants. The Senior Secured Credit Facilities also contain negative covenants that restrict the Company’s ability to (i) incur additional indebtedness; (ii) create certain liens; (iii) consolidate or merge; (iv) sell assets, including capital stock of the Company’s subsidiaries; (v) engage in transactions with the Company’s affiliates; (vi) create restrictions on the payment of dividends or other amounts to Greatbatch Ltd. from the Company’s restricted subsidiaries; (vii) pay dividends on capital stock or redeem, repurchase or retire capital stock; (viii) pay, prepay, repurchase or retire certain subordinated indebtedness; (ix) make investments, loans, advances and acquisitions; (x) make certain amendments or modifications to the organizational documents of the Company or its subsidiaries or the documentation governing other senior indebtedness of the Company; and (xi) change the Company’s type of business. These negative covenants are subject to a number of limitations and exceptions that are described in the Senior Secured Credit Facilities agreement. As of July 1, 2016, the Company was in compliance with all financial and negative covenants under the Senior Secured Credit Facilities. The Senior Secured Credit Facilities provide for customary events of default. Upon the occurrence and during the continuance of an event of default, the outstanding advances and all other obligations under the Senior Secured Credit Facilities become immediately due and payable. The Senior Secured Credit Facilities are guaranteed by Integer Holdings Corporation, as a parent guarantor, and all of the Company’s present and future direct and indirect wholly-owned domestic subsidiaries (other than Greatbatch Ltd. (which is the borrower under the Senior Secured Credit Facilities), non-wholly owned joint ventures, and certain other excluded subsidiaries). The Senior Secured Credit Facilities are secured, subject to certain exceptions, by a first priority security interest in; i) the present and future shares of capital stock of (or other ownership or profit interests in) Greatbatch Ltd. and each guarantor (except Integer Holdings Corporation); ii) sixty-six percent (66%) of all present and future shares of voting capital stock of each specified first-tier foreign subsidiary; iii) substantially all of the Company’s, Greatbatch Ltd.’s and each other guarantor’s other personal property; and iv) all proceeds and products of the property and assets of the Company, Greatbatch Ltd. and the other guarantors. 9.125% Senior Notes due 2023 - On October 27, 2015, the Company completed a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”). Interest on the Senior Notes is payable on May 1 and November 1 of each year, beginning on May 1, 2016. The Company may redeem the Senior Notes, in whole or in part, prior to November 1, 2018 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to November 1, 2018, the Company may redeem up to 40% of the aggregate principal amount of the Senior Notes using the proceeds from certain equity offerings at a redemption price equal to 109.125% of the aggregate principal amount of the Senior Notes. As of July 1, 2016, the estimated fair value of the Senior Notes was approximately $365 million, based on quoted market prices of these Senior Notes, recent sales prices for the Senior Notes and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy.
The Senior Notes are senior unsecured obligations of the Company. The indenture for the Senior Notes contains restrictive covenants that, among other things, limit the ability of the Company to: (i) incur or guarantee additional indebtedness or issue certain disqualified stock or preferred stock; (ii) create certain liens; (iii) pay dividends or make distributions in respect of capital stock; (iv) make certain other restricted payments; (v) enter into agreements that restrict certain dividends or other payments; (vi) enter into sale-leaseback agreements; (vii) engage in certain transactions with affiliates; and (viii) consolidate or merge with, or sell substantially all of their assets to, another person. These covenants are subject to a number of limitations and exceptions that are described in the indenture for the Senior Notes. The indenture for the Senior Notes provides for customary events of default, subject in certain cases to customary cure periods, in which the Senior Notes and any unpaid interest would become due and payable. As of July 1, 2016, the Company was in compliance with all restrictive covenants under the Senior Notes. As of July 1, 2016, the weighted average interest rate on all outstanding borrowings is 5.67%. Contractual maturities under the Senior Secured Credit Facilities and Senior Notes for the remainder of 2016 and the five years and thereafter, excluding any discounts or premiums, as of July 1, 2016 are as follows (in thousands):
Interest Rate Swaps – From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on its outstanding variable rate debt. On June 20, 2016, the Company entered into a three-year $200 million interest rate swap with an effective date of June 27, 2017. The Company entered into the swap to hedge against potential changes in cash flows on the outstanding TLA Facility borrowings, which are indexed to the one-month LIBOR rate. The variable rate received on the interest rate swap and the variable rate paid on the TLA Facility will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The swap is being accounted for as a cash flow hedge. During 2012, the Company entered into a three-year $150 million interest rate swap, which amortized $50 million per year. During 2014, the Company entered into an additional interest rate swap. The first $45 million of notional amount of the swap was effective February 20, 2015 and the second $45 million of notional amount was scheduled to be effective February 22, 2016. These swaps were accounted for as cash flow hedges. As a result of the Lake Region Medical acquisition, the forecasted cash flows that the Company’s interest rate swaps were hedging were no longer expected to occur. During the fourth quarter of 2015, the Company terminated these interest rate swap agreements. Information regarding the Company’s outstanding interest rate swap as of July 1, 2016 is as follows (dollars in thousands):
The estimated fair value of the interest rate swap agreement represents the amount the Company expects to receive (pay) to terminate the contract. No portion of the change in fair value of the Company’s interest rate swaps during the six months ended July 1, 2016 and July 3, 2015 was considered ineffective. The amount recorded as Interest Expense during the six months ended July 3, 2015 related to the Company’s interest rate swaps was $0.5 million.
Debt Issuance Costs and Discounts – The change in deferred debt issuance costs related to the Company’ Revolving Credit Facility is as follows (in thousands):
The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands):
|
Benefit Plans |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BENEFIT PLANS | BENEFIT PLANS The Company is required to provide its employees located in Switzerland, Mexico, France, and Germany certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico, France, and Germany are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The change in net defined benefit plan liability is as follows (in thousands):
Net defined benefit cost is comprised of the following (in thousands):
|
Stock-Based Compensation |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION At the 2016 Annual Meeting of Stockholders held on May 24, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan provides for the granting of stock options, shares of restricted stock, restricted stock units, stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers. The 2016 Plan supplements the Company’s existing 2009 and 2011 Stock Incentive Plans, as amended. In connection with the Spin-off, under the provisions of the Company’s stock incentive plans, employee stock option, restricted stock awards, and restricted stock unit awards were adjusted to preserve the fair value of the awards immediately before and after the Spin-off. As such, the Company did not record any modification expense related to the conversion of the awards. Certain awards granted to employees who transferred to Nuvectra in connection with the Spin-off were canceled. As required, the Company accelerated the remaining expense related to these canceled awards of $0.5 million during the first quarter of 2016, which was classified as Other Operating Expenses, Net. The stock awards held as of March 14, 2016 were modified as follows:
The components and classification of stock-based compensation expense were as follows (in thousands):
The weighted average fair value and assumptions used to value options granted are as follows:
The following table summarizes the Company’s stock option activity:
The following table summarizes time-vested restricted stock and restricted stock unit activity:
The following table summarizes performance-vested restricted stock unit activity:
|
Other Operating Expenses, Net |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OTHER OPERATING EXPENSES, NET | OTHER OPERATING EXPENSES, NET Other Operating Expenses, Net is comprised of the following (in thousands):
2014 investments in capacity and capabilities. In 2014, the Company announced several initiatives to invest in capacity and capabilities and to better align its resources to meet its customers’ needs and drive organic growth and profitability. These included the following:
The total capital investment expected for these initiatives is between $25.0 million and $28.0 million, of which $22.9 million has been expended through July 1, 2016. Total restructuring charges expected to be incurred in connection with this realignment are between $42.0 million and $48.0 million, of which $41.2 million has been incurred through July 1, 2016. Expenses related to this initiative are recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following: •Severance and retention: $6.0 million - $7.0 million; •Accelerated depreciation and asset write-offs: $2.0 million - $3.0 million; and •Other: $34.0 million - $38.0 million Other expenses primarily consist of costs to relocate certain equipment and personnel, duplicate personnel costs, excess overhead, disposal, and travel expenditures. All expenses are cash expenditures except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands):
Orthopedic facilities optimization. In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities, and reduce dependence on outside suppliers. This initiative was completed in 2011. In 2011, the Company began construction of an orthopedic manufacturing facility in Fort Wayne, IN and transferred manufacturing operations being performed at its Columbia City, IN location into this new facility. This initiative was completed in 2012. In 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. This initiative was completed in 2013. During 2013, the Company began a project to expand its Chaumont, France facility in order to enhance its capabilities and fulfill larger volume customer supply agreements. This initiative is expected to be completed over the next year. The total capital investment expected to be incurred for these initiatives is between $30.0 million and $35.0 million, of which $29.7 million has been expended through July 1, 2016. Total expense expected to be incurred for these initiatives is between $45.0 million and $48.0 million, of which $44.2 million has been incurred through July 1, 2016. All expenses have been and will be recorded within the Greatbatch Medical segment and are expected to include the following:
Other expenses include production inefficiencies, moving, revalidation, personnel, training, consulting, and travel costs associated with these consolidation projects. All expenses are cash expenditures except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the orthopedic facilities optimization is as follows (in thousands):
Legacy Lake Region Medical consolidations. In 2014, Lake Region Medical initiated plans to close its Arvada, CO site, consolidate its two Galway, Ireland sites into one facility, and other restructuring actions that will result in a reduction in staff across manufacturing and administrative functions at certain locations. This initiative is expected to be substantially completed by the end of 2016. The total capital investment expected for this initiative since the acquisition date is between $3.0 million and $4.0 million, of which $1.7 million has been expended through July 1, 2016. Total expense expected to be incurred for this initiative since the acquisition date is between $13.0 million and $15.0 million, of which $6.4 million has been incurred through July 1, 2016. All expenses have been and will be recorded within the Lake Region Medical segment and are expected to include the following:
Other expenses primarily consist of production inefficiencies, moving, revalidation, personnel, training, consulting, and travel costs associated with these consolidation projects. All expenses are cash expenditures.
The change in accrued liabilities related to these legacy Lake Region Medical consolidation initiatives is as follows (in thousands):
Acquisition and integration costs. During the first six months of 2016, the Company incurred $1.8 million in transaction costs related to the acquisition of Lake Region Medical. These costs primarily relate to professional and consulting fees. Expenses related to this initiative were recorded to corporate unallocated expenses. Additionally, during the first six months of 2016, the Company incurred $16.0 million in Lake Region Medical integration costs, which primarily included change-in-control payments to former Lake Region Medical executives, as well as professional, consulting, severance, retention, relocation, and travel costs, of which $5.4 million are accrued as of July 1, 2016. Total expense expected to be incurred in connection with the integration of Lake Region Medical is between $40.0 million and $50.0 million, of which $21.2 million were incurred through July 1, 2016. Total capital expenditures for this initiative are expected to be between $20.0 million and $25.0 million, the incurrence of which have not been material to date. Asset dispositions, severance and other. During 2016 and 2015, the Company recorded losses in connection with various asset disposals and/or write-downs. In addition, during the first six months of 2016 and 2015, the Company incurred legal and professional costs in connection with the Spin-off of $4.4 million and $1.5 million, respectively. Total transaction related costs incurred for the Spin-off since inception were $10.4 million. Expenses related to the Spin-off were primarily recorded within the corporate unallocated and the QiG segment. Refer to Note 2 “Divestiture and Acquisition” for additional information on the Spin-off. |
Income Taxes |
6 Months Ended |
---|---|
Jul. 01, 2016 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. The effective tax rate for the first six months of 2016 includes the impact of a $1.3 million discrete tax charge related to non-deductible Lake Region Medical and Spin-off related expenses. As of July 1, 2016, the balance of unrecognized tax benefits is approximately $9.5 million. It is reasonably possible that a reduction of up to $0.1 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $8.7 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized. |
Commitments and Contingencies |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Litigation – In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. On January 26, 2016, a jury in the U.S. District Court for the District of Delaware returned a verdict finding that AVX infringed on two Integer patents and awarded Integer $37.5 million in damages. The finding is subject to post-trial proceedings, including a possible appeal by AVX. The Company has recorded no gains in connection with this litigation as no cash has been received. In January 2015, Lake Region Medical was notified by the New Jersey Department of Environmental Protection (“NJDEP”) of the NJDEP’s intent to revoke a no further action determination made by the NJDEP in favor of Lake Region Medical in 2002 pertaining to a property on which a subsidiary of Lake Region Medical operated a manufacturing facility in South Plainfield, New Jersey beginning in 1971. Lake Region Medical sold the property in 2004 and vacated the facility in 2007. In response to the NJDEP’s notice, the Company further investigated the matter and submitted a technical report to the NJDEP in August of 2015 that concluded that the NJDEP’s notice of intent to revoke was unwarranted. After reviewing the Company’s technical report, the NJDEP issued a draft response in May 2016, stating that the NJDEP would not revoke the no further action determination at that time, but would require some additional site investigation to support the Company’s conclusion. The Company is cooperating with the NJDEP and will meet with NJDEP representatives to discuss the appropriate scope of the requested additional investigation and does not expect any material impact on its consolidated results of operations to result. In December 2014, the current owner of the property commenced litigation against Lake Region Medical, one of its executive officers and other unrelated third parties, alleging that the defendants caused or contributed to alleged groundwater contamination beneath the property. The plaintiff in that case voluntarily dismissed the litigation in June 2016. The Company is a party to various other legal actions arising in the normal course of business. The Company does not expect that the ultimate resolution of any other pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future. Environmental Matters – The Company’s Collegeville, PA facility, which was acquired as part of the Lake Region Medical acquisition, is subject to two administrative consent orders entered into with the U.S. Environmental Protection Agency (the “EPA”), which require ongoing groundwater treatment and monitoring at the site as a result of historic leaks from underground storage tanks. Upon approval by the EPA of the Company’s proposed post remediation care plan, which requires a continuation of the groundwater treatment and monitoring process at the site, the Company expects that the consent orders will be terminated. The Company expects a decision from the EPA on whether the Company’s post remediation care plan has been approved during the third quarter of 2016. The groundwater treatment process at the Collegeville facility consists of a groundwater extraction and treatment system and the performance of annual sampling of a defined set of groundwater wells as a means to monitor containment within approved boundaries. As of July 1, 2016 and January 1, 2016, there was $1.1 million recorded in Other Long-Term Liabilities in the Condensed Consolidated Balance Sheets in connection with this matter for the cost of on-going remediation. The Company does not expect this environmental matter will have a material effect on its consolidated results of operations, financial position or cash flows. Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company does not expect future product warranty claims will have a material effect on its consolidated results of operations, financial position, or cash flows. However, there can be no assurance that any future customer complaints or negative regulatory actions regarding the Company’s products, which the Company currently believes to be immaterial, does not become material in the future. The change in product warranty liability was comprised of the following (in thousands):
Foreign Currency Contracts – The Company enters into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its facilities in Mexico. In connection with the Lake Region Medical acquisition, the Company terminated its outstanding forward contracts resulting in a $2.4 million payment to the foreign currency contract counterparty during the fourth quarter of 2015. As of July 1, 2016, the Company had a $0.7 million loss recorded in Accumulated Other Comprehensive Income related to these contracts, which will be amortized to Cost of Sales as the inventory, which the contracts were hedging the cash flows to produce, is sold. The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands):
Information regarding outstanding foreign currency contracts as of July 1, 2016 is as follows (dollars in thousands):
Self-Insured Medical Plan – The Company self-funds the medical insurance coverage provided to its U.S. based employees. The Company has specific stop loss coverage for claims incurred during 2016 exceeding $250 thousand per associate for legacy Greatbatch and exceeding $275 thousand per associate for legacy Lake Region Medical with no annual maximum aggregate stop loss coverage. As of July 1, 2016 and January 1, 2016, the Company had $3.5 million and $4.0 million accrued related to its self-insurance of its medical plans, respectively. This accrual is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheets and is primarily based upon claim history. Self-Insured Workers’ Compensation Trust – Prior to 2011, the Company was a member of a group self-insurance trust that provided workers’ compensation benefits to employees of the Company in Western New York (the “Trust”). Prior to being acquired by Integer, Lake Region Medical self-insured the workers’ compensation benefits provided to its employees. As of July 1, 2016, the Company utilized a traditional insurance provider for workers’ compensation coverage for all associates. During 2015, the Company received an additional assessment from the Trust of $0.9 million. As of July 1, 2016 and January 1, 2016, the Company had $2.3 million and $3.9 million accrued for workers’ compensation claims, respectively. This accrual is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheets and is primarily based upon claim history and assessments received. |
Earnings Per Share (EPS) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EARNINGS PER SHARE (EPS) | EARNINGS (LOSS) PER SHARE (“EPS”) The following table illustrates the calculation of basic and diluted EPS (in thousands, except per share amounts):
The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):
|
Accumulated Other Comprehensive Income |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACCUMULATED OTHER COMPREHENSIVE INCOME | ACCUMULATED OTHER COMPREHENSIVE INCOME Accumulated Other Comprehensive Income is comprised of the following (in thousands):
The realized loss relating to the Company’s foreign currency and interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales and Interest Expense, Net, respectively, in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). |
Fair Value Measurements |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. Foreign Currency Contracts – The fair value of foreign currency contracts were determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs included foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold, of which approximately $1.9 million is expected to be realized within the next twelve months. Interest Rate Swap – The fair value of the Company’s interest rate swap outstanding at July 1, 2016 was determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s interest rate swap will be realized as Interest Expense as interest on the TLA Facility is accrued.
The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. Refer to Note 6 “Debt” for further discussion regarding the fair value of the Company’s Senior Secured Credit Facilities and Senior Notes. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows: Long-lived Assets – The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent. Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company did not record any impairment charges related to its long-lived assets during the first six months of 2016 or 2015. Goodwill and Indefinite-lived Intangible Assets – Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples.
Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach. The Company did not record any impairment charges related to its indefinite-lived intangible assets, including goodwill, during the first six months of 2016 or 2015, respectively. See Note 5 “Intangible Assets” for additional information on the Company’s intangible assets. Cost and Equity Method Investments – The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other Expense (Income), Net, unless separately stated. The aggregate recorded amount of cost and equity method investments at July 1, 2016 and January 1, 2016 was $24.7 million and $20.6 million, respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of July 1, 2016, the Company owned 6.9% of this fund. During the six month periods ended July 1, 2016 and July 3, 2015, the Company did not recognize any impairment charges related to its cost method investments. The fair value of these investments is determined by reference to recent sales data of similar shares to independent parties in an inactive market. This fair value calculation is categorized in Level 2 of the fair value hierarchy. During the six month periods ended July 1, 2016 and July 3, 2015, the Company recognized a net gain on cost and equity method investments of $1.2 million and $0.5 million, respectively. |
Business Segment, Geographic and Concentration Risk Information |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION | BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION As a result of the acquisition of Lake Region Medical, the Company now has three reportable segments: Greatbatch Medical, QiG and Lake Region Medical. During the first quarter of 2016, the Company completed the Spin-off of a portion of its QiG segment. See Note 2 “Divestiture and Acquisition” for further description of these transactions. As a result of the Lake Region Medical acquisition and the Spin-off, the Company is re-evaluating its internal financial reporting structure, which may change its product line and segment reporting in the future. This process is expected to be finalized in 2016. Greatbatch Medical designs and manufactures medical devices and components where Integer either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical provides medical devices and components to the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets among others. Greatbatch Medical also offers value-added assembly and design engineering services for medical devices that utilize its component products. The QiG segment focuses on the design and development of complete medical device systems and components. The medical devices QiG designs and develops are full product solutions that utilize the medical technology expertise and capabilities residing within Greatbatch Medical and Lake Region Medical. QiG revenue consists primarily of sales of various medical device products such as implantable pulse generators, programmer systems, battery chargers, patient wands and leads to medical device companies. Once the medical devices developed by QiG reach significant production levels, the responsibility for manufacturing these products may be transferred to Greatbatch Medical. Lake Region Medical has operated as a segment for Integer since it was acquired during the fourth quarter of 2015. This segment specializes in the design, development, and manufacturing of products across the medical component and device spectrum, primarily serving the cardio, vascular and advanced surgical markets. Lake Region Medical offers fully integrated outsourced manufacturing, regulatory and engineering services, contract manufacturing, finished device assembly services, original device development, and supply chain management.
As a result of the Lake Region Medical acquisition and the Spin-off, the Company has recast its product line sales into the following four categories:
An analysis and reconciliation of the Company’s business segments, product lines and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped (in thousands):
(a) Greatbatch Medical sales include approximately $0.1 million and $0.3 million of intersegment sales for the three and six months ended July 1, 2016, respectively. Lake Region Medical sales include approximately $0.3 million $1.0 million of intersegment sales for the three and six months ended July 1, 2016, respectively. Intersegment sales for the three and six months periods of 2015 are included in the Greatbatch Medical segment.
Three customers accounted for a significant portion of the Company’s sales as follows:
Long-lived tangible assets by geographic area are as follows (in thousands):
|
Impact of Recently Issued Accounting Standards |
6 Months Ended | ||||
---|---|---|---|---|---|
Jul. 01, 2016 | |||||
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | |||||
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS | IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. This update requires acquiring companies to recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance in this ASU became effective for the Company on January 2, 2016. See Note 2 “Divestiture and Acquisition” for further description of the measurement-period adjustments made and the Company’s acquisition. In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB, Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Condensed Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Condensed Consolidated Financial Statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which amends the guidance on reporting credit losses for assets held at amortized cost and available-for-sale debt securities. For assets held at amortized cost, the ASU eliminates the probable initial recognition threshold and requires an entity to reflect a current estimate of all expected credit losses, such that the net amount expected to be collected is presented. For available-for-sale debt securities, the ASU requires credit losses to be presented as an allowance versus a write-down. These amendments are effective for the Company in annual and interim reporting periods beginning after December 15, 2019, with early adoption permitted in annual and interim reporting periods beginning after December 15, 2018. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09 changes how companies account for certain aspects of share-based payment awards to employees, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period and the entity must adopt all of the amendments from ASU 2016-09 in the same period. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. This ASU retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. As a result, the effect of leases on the consolidated statement of comprehensive income and a consolidated statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements.
In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” This ASU requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income; requires entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset; and requires entities to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk (also referred to as “own credit”) when the organization has elected to measure the liability at fair value in accordance with the fair value option. This ASU is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of the own credit provision is permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This ASU is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently assessing the impact of adopting this ASU on its Condensed Consolidated Financial Statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU No. 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. In August 2015, the FASB approved a one year deferral to the effective date to be adopted by all public companies for annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. In March, April and May of 2016, respectively, the FASB issued ASU No. 2016-08, which clarifies the implementation guidance on principal versus agent considerations, ASU No. 2016-10, which clarifies the implementation guidance on identifying performance obligations and licensing and ASU No. 2016-12, which provides improvements to the guidance on collectability, non-cash consideration, and completed contracts at transition, a practical expedient for contract modifications at transition and an accounting policy election related to the presentation of sales taxes and other similar taxes collected from customers. These amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. The Company is currently assessing the financial impact of adopting these ASU’s and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected. |
Summary of Significant Accounting Policies (Policies) |
6 Months Ended | ||||
---|---|---|---|---|---|
Jul. 01, 2016 | |||||
Accounting Policies [Abstract] | |||||
Interim Basis of Accounting | The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Integer Holdings Corporation and its subsidiaries (collectively “Integer” or the “Company”) for the periods presented. The January 1, 2016 condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 1, 2016. |
||||
Use of Estimates | The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. |
||||
Fiscal Period | The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The second quarter of 2016 and 2015 each contained 13 weeks, and ended on July 1, and July 3, respectively. |
||||
Income Taxes | The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. |
||||
Long Lived Assets and Finite-Lived Intangible Assets | The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent. Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company did not record any impairment charges related to its long-lived assets during the first six months of 2016 or 2015. |
||||
Goodwill and Intangible Assets | Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples.
Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach. |
||||
Cost And Equity Method Investments | The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other Expense (Income), Net, unless separately stated. |
Divestiture and Acquisition (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Divestiture and Acquisition [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of divested assets and liabilities | In connection with the Spin-off, during the first quarter of 2016, the Company made a cash capital contribution of $75 million to Nuvectra and divested the following assets and liabilities (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Assets Acquired and Liabilities Assumed | The aggregate consideration paid to the stockholders and equity award holders of Lake Region Medical consisted of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | The following table summarizes the preliminary allocation of the Lake Region Medical purchase price to the assets acquired and liabilities assumed (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] | Intangible Assets – The purchase price was allocated to intangible assets as follows (dollars in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Acquisition Pro Forma Results | The following unaudited pro forma information presents the consolidated results of operations of the Company and Lake Region Medical as if that acquisition occurred as of the beginning of fiscal year 2014 (in thousands, except per share amounts):
|
Supplemental Cash Flow Information (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Cash Flow Elements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Cash Flow, Supplemental Disclosures |
|
Inventories (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory, Current | Inventories are comprised of the following (in thousands):
|
Intangible Assets (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets, Major Class | Amortizing intangible assets are comprised of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets, Amortization Expense | Aggregate intangible asset amortization expense is comprised of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense | Estimated future intangible asset amortization expense based on the carrying value as of July 1, 2016 is as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Indefinite-Lived Intangible Assets and Goodwill | Indefinite-lived intangible assets are comprised of the following (in thousands):
The change in goodwill is as follows (in thousands):
|
Debt (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Long-Term Debt | Long-term debt is comprised of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Maturities of Long-term Debt | Contractual maturities under the Senior Secured Credit Facilities and Senior Notes for the remainder of 2016 and the five years and thereafter, excluding any discounts or premiums, as of July 1, 2016 are as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Interest Rate Derivatives | Information regarding the Company’s outstanding interest rate swap as of July 1, 2016 is as follows (dollars in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Deferred Financing Fees | The change in deferred debt issuance costs related to the Company’ Revolving Credit Facility is as follows (in thousands):
The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands):
|
Benefit Plans (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Defined Benefit Plan, Change in Benefit Obligation | The change in net defined benefit plan liability is as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Net Defined Benefit Cost | Net defined benefit cost is comprised of the following (in thousands):
|
Stock-Based Compensation (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs | The components and classification of stock-based compensation expense were as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | The weighted average fair value and assumptions used to value options granted are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options Activity | The following table summarizes the Company’s stock option activity:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity | The following table summarizes time-vested restricted stock and restricted stock unit activity:
The following table summarizes performance-vested restricted stock unit activity:
|
Other Operating Expenses, Net (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Other Operating Cost and Expense By Component | Other Operating Expenses, Net is comprised of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments in Capacity and Capabilities [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve By Type of Cost | The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Orthopaedic Facility Optimization [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve By Type of Cost | The change in accrued liabilities related to the orthopedic facilities optimization is as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Legacy Lake Region Medical Consolidation [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve By Type of Cost | The change in accrued liabilities related to these legacy Lake Region Medical consolidation initiatives is as follows (in thousands):
|
Commitments and Contingencies (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Product Warranty Liability | The change in product warranty liability was comprised of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance | The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Foreign Exchange Contracts, Statement of Financial Position | Information regarding outstanding foreign currency contracts as of July 1, 2016 is as follows (dollars in thousands):
|
Earnings Per Share (EPS) (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Calculation of Numerator and Denominator in Earnings Per Share | The following table illustrates the calculation of basic and diluted EPS (in thousands, except per share amounts):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):
|
Accumulated Other Comprehensive Income (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income is comprised of the following (in thousands):
|
Fair Value Measurements (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
|
Business Segment, Geographic and Concentration Risk Information (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reconciliation [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Revenue from Segments to Consolidated | Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped (in thousands):
(a) Greatbatch Medical sales include approximately $0.1 million and $0.3 million of intersegment sales for the three and six months ended July 1, 2016, respectively. Lake Region Medical sales include approximately $0.3 million $1.0 million of intersegment sales for the three and six months ended July 1, 2016, respectively. Intersegment sales for the three and six months periods of 2015 are included in the Greatbatch Medical segment. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Geographic Areas, Revenues from External Customers [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Revenue From External Customers Attributed to Foreign Countries By Geographic Area |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Revenue By Major Customers By Reporting Segments | Three customers accounted for a significant portion of the Company’s sales as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Geographic Areas, Long-Lived Assets [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Long-Lived Assets By Geographical Areas | Long-lived tangible assets by geographic area are as follows (in thousands):
|
Summary of Significant Accounting Policies (Basis of Presentation) (Details) - Segment |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Accounting Policies [Abstract] | ||||
Fiscal Period Duration | 91 days | 91 days | 182 days | 182 days |
Number of Reportable Segments | 3 |
Divestiture and Acquisition Divestiture and Acquisition (Spin-off of Nuvectra Corporation) (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Mar. 14, 2016
USD ($)
|
Apr. 01, 2016
USD ($)
|
Jul. 03, 2015
USD ($)
|
Jul. 03, 2015
USD ($)
|
Jul. 01, 2016
USD ($)
|
Jan. 01, 2016
USD ($)
|
|
Liabilities transferred | ||||||
Accounts receivable, net | $ 192,121 | $ 207,342 | ||||
Nuvectra [Member] | ||||||
Liabilities transferred | ||||||
Accounts receivable, net | $ 4,600 | |||||
Spin-off [Member] | Nuvectra [Member] | ||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||
Stock conversion ratio | 3 | |||||
Cash capital contribution | $ 75,000 | |||||
Assets divested | ||||||
Cash and cash equivalents | $ 76,256 | |||||
Other current assets | 977 | |||||
Property, plant and equipment, net | 4,407 | |||||
Amortizing intangible assets, net | 1,931 | |||||
Goodwill | 40,830 | |||||
Deferred income taxes | 6,446 | |||||
Total assets | 130,847 | |||||
Liabilities transferred | ||||||
Current liabilities | 2,119 | |||||
Net assets divested | $ 128,728 | |||||
Pre-tax loss | $ 5,200 | $ 6,200 | $ 11,700 |
Divestiture and Acquisition (Summary of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands |
Oct. 27, 2015 |
Jul. 01, 2016 |
Jan. 01, 2016 |
---|---|---|---|
Assets acquired | |||
Goodwill | $ 980,839 | $ 1,013,570 | |
Lake Region Medical [Member] | |||
Business Acquisition [Line Items] | |||
Cash | $ 478,490 | ||
Total purchase consideration | 728,366 | ||
Assets acquired | |||
Current assets | 269,815 | ||
Property, plant and equipment | 216,473 | ||
Amortizing intangible assets | 849,000 | ||
Indefinite-lived intangible assets | 70,000 | ||
Goodwill | 665,720 | ||
Other non-current assets | 1,629 | ||
Total assets acquired | 2,072,637 | ||
Liabilities assumed | |||
Current liabilities | 103,836 | ||
Debt assumed | 1,044,675 | ||
Other long-term liabilities | 195,760 | ||
Total liabilities assumed | 1,344,271 | ||
Net assets acquired | 728,366 | ||
Stock Option [Member] | Lake Region Medical [Member] | |||
Business Acquisition [Line Items] | |||
Equity interests | 4,508 | ||
Common Stock [Member] | Lake Region Medical [Member] | |||
Business Acquisition [Line Items] | |||
Equity interests | $ 245,368 |
Divestiture and Acquisition (Summary of Acquisition Pro Forma Results) (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 6 Months Ended |
---|---|---|
Jul. 03, 2015 |
Jul. 03, 2015 |
|
Business Acquisition [Line Items] | ||
Sales | $ 377,934 | $ 736,351 |
Net income | $ 4,709 | $ 5,675 |
Earnings per share: | ||
Basic (in dollars per share) | $ 0.15 | $ 0.18 |
Diluted (in dollars per share) | $ 0.15 | $ 0.18 |
Divestiture and Acquisition (Narrative) (Details) - USD ($) $ in Thousands |
6 Months Ended | |
---|---|---|
Oct. 27, 2015 |
Jul. 01, 2016 |
|
Business Acquisition [Line Items] | ||
Goodwill, measurement-period adjustment | $ 3,932 | |
Lake Region Medical [Member] | ||
Business Acquisition [Line Items] | ||
Total purchase price and debt assumed | $ 1,770,000 | |
Repayments of Debt | $ 1,000,000 | |
Reason for Acquisition | The Company believes that the combination of Greatbatch and Lake Region Medical brings together two highly complementary organizations that can provide a new level of industry leading capabilities and services to OEM customers while building value for stockholders. | |
Goodwill, measurement-period adjustment | 3,900 | |
Deferred Tax Liability, measurement-period adjustment | 2,600 | |
Revenue since acquisition | 403,200 | |
Net loss since acquisition | $ 16,500 | |
Increase in Inventory | $ 23,000 |
Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands |
6 Months Ended | |
---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Noncash investing and financing activities: | ||
Common stock contributed to 401(k) Plan | $ 0 | $ 3,920 |
Property, plant and equipment purchases included in accounts payable | 9,696 | 1,446 |
Purchase of technology included in accrued expenses | 1,000 | 0 |
Divestiture of noncash assets | 54,591 | 0 |
Divestiture of liabilities | $ 2,119 | $ 0 |
Inventories (Details) - USD ($) $ in Thousands |
Jul. 01, 2016 |
Jan. 01, 2016 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw materials | $ 114,454 | $ 107,296 |
Work-in-process | 103,747 | 93,729 |
Finished goods | 58,078 | 51,141 |
Total | $ 276,279 | $ 252,166 |
Intangible Assets (Schedule of Finite-Lived Intangible Assets, Amortization Expense) (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jul. 01, 2016 |
Apr. 01, 2016 |
Jul. 03, 2015 |
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Finite-Lived Intangible Assets [Line Items] | |||||
Acquired Finite-Lived Intangible Asset | $ 2,000 | ||||
Weighted Average Amortization Period (Years) | 15 years | ||||
Finite Lived Intangible Assets, Amortization Expense | $ 9,514 | $ 3,378 | $ 18,978 | $ 6,765 | |
Cost of Sales [Member] | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Finite Lived Intangible Assets, Amortization Expense | 4,240 | 1,445 | 8,480 | 2,916 | |
Selling General And Administrative Expense [Member] | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Finite Lived Intangible Assets, Amortization Expense | 5,123 | 1,830 | 10,259 | 3,643 | |
Research and Development Expense [Member] | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Finite Lived Intangible Assets, Amortization Expense | $ 151 | $ 103 | $ 239 | $ 206 |
Intangible Assets Intangible Assets (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) - USD ($) $ in Thousands |
Jul. 01, 2016 |
Jan. 01, 2016 |
---|---|---|
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] | ||
Remainder of 2016 | $ 18,934 | |
2017 | 44,050 | |
2018 | 44,962 | |
2019 | 45,044 | |
2020 | 45,642 | |
Thereafter | 681,622 | |
Total estimated amortization expense | $ 880,254 | $ 893,977 |
Debt (Long-term Debt Maturity Schedule) (Details) $ in Thousands |
Jul. 01, 2016
USD ($)
|
---|---|
Debt Disclosure [Abstract] | |
Remaining in 2016 | $ 14,500 |
2017 | 31,344 |
2018 | 40,719 |
2019 | 47,750 |
2020 | 102,750 |
Thereafter | 1,563,437 |
Total | $ 1,800,500 |
Benefit Plans (Schedule of Defined Benefit Plan, Change in Benefit Obligation) (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] | ||||
At January 1, 2016 | $ 7,121 | |||
Net defined benefit cost | $ 198 | $ 102 | 390 | $ 207 |
Benefit payments | (70) | |||
Foreign currency translation | 116 | |||
At July 1, 2016 | $ 7,557 | $ 7,557 |
Benefit Plans (Schedule of Net Defined Benefit Cost) (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract] | ||||
Service cost | $ 110 | $ 78 | $ 218 | $ 157 |
Interest cost | 45 | 15 | 88 | 30 |
Amortization of net loss | 47 | 12 | 93 | 26 |
Expected return on plan assets | (4) | (3) | (9) | (6) |
Net defined benefit cost | $ 198 | $ 102 | $ 390 | $ 207 |
Stock-Based Compensation (Valuation Assumptions) (Details) - $ / shares |
6 Months Ended | |
---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Weighted average fair value | $ 9.41 | $ 12.18 |
Risk-free interest rate | 1.58% | 1.55% |
Expected volatility | 26.00% | 26.00% |
Expected life (in years) | 5 years | 5 years |
Expected dividend yield | 0.00% | 0.00% |
Stock-Based Compensation Stock-Based Compensation (Impact of Spin-off) (Details) (Details) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 14, 2016 |
Apr. 01, 2016
USD ($)
|
|
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Acceleration of remaining compensation expense | $ 0.5 | |
Adjusted Exercise Price due to Spin-off, percentage | 93.00% | |
Spin-off [Member] | Nuvectra [Member] | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 3 |
Income Taxes (Narrative) (Details) $ in Millions |
6 Months Ended |
---|---|
Jul. 01, 2016
USD ($)
| |
Income Tax Disclosure [Abstract] | |
Discrete tax charges related to non-deductible Lake Region Medical and Spin-off | $ 1.3 |
Unrecognized Tax Benefits | 9.5 |
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit | 0.1 |
Unrecognized Tax Benefits that Would Impact Effective Tax Rate | $ 8.7 |
Commitments and Contingencies (Schedule of Product Warranty Liability) (Details) $ in Thousands |
6 Months Ended |
---|---|
Jul. 01, 2016
USD ($)
| |
Movement in Standard Product Warranty Accrual [Roll Forward] | |
At January 1, 2016 | $ 3,316 |
Additions to warranty reserve | 1,163 |
Warranty claims settled | (1,427) |
At July 1, 2016 | $ 3,052 |
Earnings Per Share (EPS) (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] | ||||
Net income (loss) | $ (770) | $ 9,283 | $ (13,430) | $ 17,291 |
Weighted Average Number of Shares Outstanding Reconciliation [Abstract] | ||||
Basic | 30,767,000 | 25,473,000 | 30,743,000 | 25,369,000 |
Effect of dilutive securities stock options, restricted stock and restricted stock units | 0 | 840,000 | 0 | 895,000 |
Denominator for diluted EPS | 30,767,000 | 26,313,000 | 30,743,000 | 26,264,000 |
Basic EPS (in dollars per share) | $ (0.03) | $ 0.36 | $ (0.44) | $ 0.68 |
Diluted EPS (in dollars per share) | $ (0.03) | $ 0.35 | $ (0.44) | $ 0.66 |
Anitdilutive Securities Excluded From Earnings Per Share [Abstract] | ||||
Time-vested stock options, restricted stock and restricted stock units | 1,916,000 | 276,000 | 1,916,000 | 297,000 |
Performance-vested stock options and restricted stock units | 417,000 | 60,000 | 417,000 | 56,000 |
Fair Value Measurements Fair Value Measurements (Narrative) (Details) - USD ($) |
6 Months Ended | ||
---|---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
Jan. 01, 2016 |
|
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | |||
Foreign currency cash flow hedge gain (loss) to be reclassified | $ 1,900,000 | ||
Long-lived asset impairment loss | 0 | $ 0 | |
Goodwill impairment loss | 0 | 0 | |
Indefinite-lived intangible assets (excluding goodwill) impairment loss | 0 | 0 | |
Cost-method investment impairment loss | 0 | 0 | |
Equity method investments, carrying value | 24,700,000 | $ 20,600,000 | |
Fair Value, Inputs, Level 2 [Member] | |||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | |||
Gain on cost method and equity method investments | $ 1,200,000 | $ 500,000 | |
Chinese Venture Capital Fund [Member] | |||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | |||
Equity method investment ownership (percent) | 6.90% |
Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Schedule of Revenue From External Customers Attributed to Foreign Countries By Geographic Area) (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Revenue, Major Customer [Line Items] | ||||
Sales Revenue, Net | $ 348,382 | $ 174,890 | $ 680,620 | $ 336,210 |
UNITED STATES | ||||
Revenue, Major Customer [Line Items] | ||||
Sales Revenue, Net | 204,090 | 75,041 | 406,213 | 145,557 |
PUERTO RICO | ||||
Revenue, Major Customer [Line Items] | ||||
Sales Revenue, Net | 39,344 | 37,415 | 78,472 | 71,431 |
BELGIUM | ||||
Revenue, Major Customer [Line Items] | ||||
Sales Revenue, Net | 20,491 | 16,018 | 38,657 | 33,385 |
Rest Of World [Member] | ||||
Revenue, Major Customer [Line Items] | ||||
Sales Revenue, Net | $ 84,457 | $ 46,416 | $ 157,278 | $ 85,837 |
Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Schedule of Revenue By Major Customers By Reporting Segments) (Details) - customer |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 01, 2016 |
Jul. 03, 2015 |
Jul. 01, 2016 |
Jul. 03, 2015 |
|
Revenue, Major Customer [Line Items] | ||||
Revenue Major Customer Percent | 45.00% | 50.00% | 46.00% | 52.00% |
Customer A [Member] | ||||
Revenue, Major Customer [Line Items] | ||||
Revenue Major Customer Percent | 17.00% | 20.00% | 18.00% | 21.00% |
Customer B [Member] | ||||
Revenue, Major Customer [Line Items] | ||||
Revenue Major Customer Percent | 15.00% | 18.00% | 15.00% | 18.00% |
Customer C [Member] | ||||
Revenue, Major Customer [Line Items] | ||||
Revenue Major Customer Percent | 13.00% | 12.00% | 13.00% | 13.00% |
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | ||||
Revenue, Major Customer [Line Items] | ||||
Concentration risk, number of customers | 3 |
Business Segment, Geographic And Concentration Risk Information (Schedule of Long-Lived Assets By Geographical Areas) (Details) - USD ($) $ in Thousands |
Jul. 01, 2016 |
Jan. 01, 2016 |
---|---|---|
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Property, plant and equipment, net | $ 383,229 | $ 379,492 |
UNITED STATES | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Property, plant and equipment, net | 265,208 | 264,556 |
Rest Of World [Member] | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Property, plant and equipment, net | $ 118,021 | $ 114,936 |
Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Narrative) (Details) |
6 Months Ended |
---|---|
Jul. 01, 2016
Segment
| |
Segment Reporting Information [Line Items] | |
Number of Reportable Segments | 3 |
^,6CLZLK'-W%D3$;O?3>(57R4\K1,$K$]LIZ*!3^Q
M03W9\[&G4DW'0R).(Z,[8^J[! % DIZV0UQ7YM[+6%?\++MV8"]C),Y]3\>_
M:];QZRJ&\>W&:WLX2GTCJ:OD[MNU/1M$RX=H9/M5_ 4N&XBUQ"A^M>PJG'&D
MX3> X%X*C'>+'&-^<0DV3%)
M5@+'39,U)MTV.>Z8'%<"CYLF:\R7;9-TQR1="L3AILD:\W]/X$4+"E"UOVD:
M%;)OS=AK\^I\F9]\S^,/>)YUM(:?5-6LU>@JC;T(OI4K*0W8),('>YZ-?6[F
M@$-EW#2U %TF(&2"A4RR
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MN;]Z2/&)S*(24=]"S7LU4A0CMRA&Y NX(D.=($4QPOT50AWB,(R" U*Y"%X
M2;$I6 I1]&T.TDCQA\LS[OI1&BT/N4@1B(M=U'":GHS,IW9/ZX8JT1R'IJ]U
M=O)2J['MF=_.C>43#-W4EWF6GO.C^)4WQZ)NG3>INIYLZ*H.4BK1Q<$>NHQ/
M7>L[/Y3BH/K;J+MOQF9P?%#R?.MMYP8[^P]02P,$% @ SX,)2<*+,$"/
M @ *@H !D !X;"]W;W)KY&H]V2[83R4^W$\;]F%/_ U!+ P04
M " #/@PE):])*+1<% "&& & 'AL+W=O
[)
M@U\@WA"(G4 \E[CSEKC&Q'Z39,,D60DD7I,U9N\WV6^8[%<"J==DC;GWFZ0;
M)NE*X,%KLL(DX3\F^.8(Y$D*#"1'>F?ULS'.S#!A4VG93TY?3#9P&6O37]V1YU/(O4$L#
M!!0 ( ,^#"4G_V Y@K $ !8$ 9 >&PO=V]R:W-H965T
OT.40&L&,4VF_*+M)Q=F#XB!&/MNVK&S;M"MAW-&F
M";@CX)X0>]9X&\C:_$$421/!&R3:O:V).4)_C_5&9$A[DXY9LMD;1)K<4[P-
M$_=NA$:84XO!%N/W"%>K]R'P?(@3'M#Q-#U8M YW$X+;!8$-E9@TPE$
MDRF.,?%TD' A2#@2V$T+;!<$MFO2C!8$HJR)M,8W;+)YH;)9B9POV@RP^RB99/DADDR
M$X@73>:8[^=-KKI#@*K\)= HEWUK0AM,J],]>Z"^N[[@6=JQ"OXQ536M1B=I
M;(_Z+BNE-&"3B.YLJ;5]":: 0VG<=&OG*ER.$!C97:[Z]-YDGU!+ P04
M" #/@PE)>K&L40('IA0>B%=X&(MFG=W6'A@3)&Y[#-,
M8FRQS^51_"R[8]7VT8LJ\F[\K
MYHM!GC\^DV[?:IM_4$L#!!0 ( ,^#"4DUPTB@Q@( *<* 9 >&PO
M=V]R:W-H965T\>L-@4;4